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Despite the availability of antibacterial agents, tuberculosis (TB) remains the leading cause of death by 
a single infectious agent globally, accounting for millions of deaths annually. The high mortality and 
morbidity rates are associated with antibiotic resistance and tolerance. Further, Mycobacterium 
tuberculosis, the causative agent of TB, has successfully evolved various strategies to evade an 
antibacterial immune response. M. tuberculosis infection is a continuous interaction between the host 
and the bacterium. An improved fundamental understanding of how this bacterium can survive within 
host immune cells has paved the way for the development of host directed therapies (HDT) that utilize a 
different approach to conventional antibiotics; and such strategies are desperately required for the 
eradication of TB.  
HDT is an approach targeted at the host immune system instead of M. tuberculosis itself. By targeting 
the host immune system, there is potential to restrict the possible acquisition of genetic resistance, since 
the bacteria itself is not the target. To favour a protective immune response at the molecular level, 
immunotherapeutic nanoparticles (NPs) are being exploited. NPs are particulate structures at the 
nanoscale (1 – 1000 nm) with the ability to target specific cells, with such targeting achieved through 
modification of the surface of the NP with bioactive ligands. By targeting specific cells, the NPs can 
localize at the pathogen infected site and elicit an antibacterial response through ligand-receptor 
interactions.  
In this study, to target M. tuberculosis-infected macrophages (primary host immune cells), poly(lactide-
co-glycolide) (PLGA) NPs were functionalised with curdlan, an immune-stimulatory polysaccharide 
known to target the dectin-1 receptor expressed on macrophages. Curdlan-dectin-1 interactions are 
known to stimulate the NF-kβ pathway that produces bactericidal factors such as oxidative species and 
pro-inflammatory cytokines and activate downstream pathways capable of killing intracellular bacilli. 
Thus, it is hypothesized that the introduction of curdlan-functionalised PLGA (C-PLGA) NPs to M. 
tuberculosis infected macrophages will stimulate the cells, leading to the death of the intracellular bacilli.   
Four different formulations were synthesized containing different curdlan loads and these included 
PLGA, 2%, 5% and 8% w/w C-PLGA NPs. Dynamic light scattering data confirmed the particles to be 
in the nano-size range with a negative zeta potential. The cytotoxicity of the NPs towards RAW264.7 
macrophages was assessed using the MTT assay over 72h. Macrophages infected with M. tuberculosis 
ΔleuDΔpanD::pMV306hsp+lux expressing the bacterial luciferase gene, were used to assess the killing 
efficacy of the NPs (using luminescence as a proxy for cell numbers, with confirmatory colony forming 
unit (CFU) plating). While CFU data showed a trend towards reduction in M. tuberculosis bacterial 
numbers compared to untreated control following NP treatment, interpretation of results was cofounded 
by possible macrophage lysis, and this will require further investigation. Cytokine quantification 
highlighted the immune stimulating capabilities of the curdlan-functionalised NPs and upregulation of 
TNF-α was detected after 72h. The findings of this study support the hypothesis that C-PLGA NPs can 
stimulate M. tuberculosis infected macrophages, potentially leading to death of intracellular M. 




Ten spyte van beskikbare antibakteriële middels, bly tuberkulose (TB) die grootste oorsaak van sterftes 
deur 'n enkele infektiewe agent wêreldwyd en lei tot miljoene sterftes jaarliks. Die hoë mortaliteit en 
morbiditeit syfers word geassosieer met antibiotika weerstandigheid en verdraagsaamheid. Verder het 
Mycobacterium tuberculosis, die oorsaak van TB, verskeie strategieë ontwikkel om 'n antibakteriële 
immuunrespons suksesvol te ontduik. M. tuberculosis infeksies is 'n deurlopende interaksie tussen die 
gasheer en die bakterieë. ‘n Goeie begrip oor hoe hierdie bakterieë kan oorleef binne die gasheer se 
immuunselle het die weg gebaan vir die ontwikkeling van gasheer-gerigte terapie wat 'n ander benadering 
tot konvensionele antibiotika gebruik. 
Gasheer-gerigte terapie is 'n benadering wat direk gerig is op die gasheer se immuunsisteem in plaas van 
M. tuberculosis self. Deur die gasheer se immuunstelsel te teiken, is dit moontlik om die ontwikkeling
van genetiese weerstand te beperk, aangesien die bakterieë self nie geteikin word nie. Om die
immuunrespons op ‘n molekulêre vlak te kan beheer, word immunoterapeutiese nanopartikels (NPs)
ingespan. NPs is baie klein strukture op die nanoskaal (1 – 1000 nm) met die vermoë om spesifieke selle
te teiken. Dit word moontlik gemaak deur die oppervlak van die NP met bioaktiewe molekules te
verweisig. Dus, deur spesifieke selle te teiken, kan die NPs ‘n gelokaliseerde antibakteriële reaksie ontlok
deur middel van ligand-reseptor interaksies.
Om M. tuberculosis-geïnfekteerde makrofage te teiken (primêre gasheer sel) word poly(lactide-co-
glycolide) (PLGA) NPs geweisig met curdlan, 'n immuun-stimulerende polisakkaried gerig to die dectin-
1 reseptor op die oppervlak van makrofage. Curdlan-dectin-1 interaksies stimuleer die NF-kβ weg wat 
lei tot die vrystellling van verskeie antibakteriële faktore soos oksidatiewe spesies en pro-
inflammatoriese molekules en gevolgelik verskeie paaie stroomaf aktiveer wat in staat is om 
intrasellulêre patogene dood te maak. Die hipotese is dus dat die aanwending van curdlan-geweisigde 
PLGA (C-PLGA) NPs geïnfekteerde immunselle sal stimuleer, wat lei tot die dood van die intrasellulêre 
bakterieë. 
Vier verskillende NP formulerings is geproduseer met verskillende hoeveelhede curdlan en sluit in 
PLGA, 2%, 5% en 8% C-PLGA NPs. Dinamiese lig verstrooiing (DLV) data het bevestig dat die NPs 
van nano-grootte is met 'n negatiewe zeta potensiaal en stabiel voorkom in ‘n oplossing. Die sellulêre 
toksisiteit van die NPs is geassesseer oor 72 uur op RAW264.7 makrofage deur middel van die MTT 
toets. Makrofage is geïnfekteer met M. tuberculosis ΔleuDΔpanD::pMV306hsp + Lux  wat ons in staat 
stel om die groei inhiberende potensiaal van die NPs te meet deur verandering in luminessensie te gebruik 
as ‘n aanduiding van seldood gevolg deur die tel van kolonie vormende eenhede (KVE). Terwyl KVE 
data 'n afname in M. tuberculosis selgetalle toon vir die NP behandelde selle in vergelyking met 
luminessensie is die resultate verwarrend moontlik as gevolg van die makrofage wat liseer en dus sal dit 
verdere ondersoek vereis. Sitokien kwantifisering het die immuunstimulerende vermoëns van die 
curdlan-verweisigde NPs uitgelig en ‘n verhoogde uitdrukking van TNF-α is na 72 uur opgespoor. Die 
bevindinge van hierdie studie ondersteun die hipotese dat C-PLGA NPs ‘n immuunresponse kan 
stimuleer in M. tuberculosis geïnfekteerde makrofage en dus lei tot 'n dood van intrasellulêre patogene. 






I would like to sincerely say thank you to the following people that continued to be my ultimate 
supporters throughout this process: 
 
 To my supervisor, Prof. Samantha Sampson. A “thank you” is not nearly enough to justify 
what you meant to me and this project but here goes. Thank you for understanding me 
better than I could understand myself and dealing with the language gap that arose in very 
inconvenient times. Thank you for always being willing to listen and brainstorm, the 
knowledge cropped up within you is something incredible. Thank you for being the best 
example of what a mentor should be, I feel privileged to have been under your wing for 
the past two years. You are exactly who young scientists want to be when they grow up! 
Thank you for pushing me, believing in me and sharing your love of dogs with me. I will 
always be grateful. Thank you for sharing your love for science with the world! 
 
 To my co-supervisor, Prof. Admire Dube. Thank you for always being there to help, assist 
and brainstorm. Thank you for being one of the most positive people I have ever come 
across, it rubs off, trust me. Thank you for sharing your love for nanomedicine with me, 
the passion for this is clearly visible and inspiring.  
 
 To my lab members, thank you for being a part of this project, either directly or not I 
appreciate it more than you will know.  
 
 To my friends, family and most importantly parents. Thank you for being my backbone 
and for supporting me and loving me and just being present! You were instrumental in 
getting me through this degree. Ek is baie lief vir julle!  
 
 I would like to say thank you to my funders, the National Research Foundations (NRF) 








List of Publications 
Raymonde B. Bekale, Su-Mari Du Plessis, Nai-Jen Hsu, Jyoti R. Sharma, Samantha L. Sampson, 
Muazzam Jacobs, Mervin Meyer, Gene D. Morse, Admire Dube. Mycobacterium Tuberculosis and 
Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics 
and Vaccines. 
Pharmaceutical Research. 2019. Vol 36.  DOI:10.1007/s11095-018-2528-9 




AA Arachidonic acid 
AG Arabinogalactan 
APCs Antigen presenting cells 
ATP Adenosine triphosphate 
BCG Bacillus Calmette-Guerin 
CaM Calmodulin 
CFU Colony forming unit 
CLRs C-type lectin receptors 
CORVET  Core vacuole/endosome tether 
DCs Dendritic cells 
EEAI Early endosomal antigen 1 
ER Endoplasmic reticulum 
HBHA Heparin binding hemagglutinin adhesion protein 
HIV Human immunodeficiency virus 
IFN Interferon 
IL Interleukin 
IMCs Immune modulating compounds 
INH Isoniazid 




LAMP Lysosome-associated membrane proteins 
LBPA Lysobisphosphatidic acid 
LM Lipomannan 
LTBI Latent tuberculosis infection 
M. tuberculosis Mycobacterium tuberculosis 
Man-LAM Mannosylated-lipoarabinomannan 
MAs Mycolic acids 
MDR-TB Multi-drug resistant tuberculosis 
mg Milligram 




NLRs Nod-like receptors 
nm Nanometer 
NO Nitric oxide 
NPs Nanoparticles 
NRP Non-replicating persistent 
PA Phosphatidic acid 
PAMPs Pathogen associated molecular patterns 
PCL Polycaprolactone 
PDI Polydispersity index 
PG Peptidoglycan 
PI5P Phosphatidylinositol 5-phosphate 
PIM Phosphatidylinositol mannoside 
PIP3 Phosphatidylinositol 3-phosphate 
PLGA Poly(lactide-co-glycolide) 





PtpA Protein tyrosine phosphatase 
RIF Rifampicin 
ROS/RNS Reactive oxygen and nitrogen species 
rpm Revolutions per minute 
SIP Sphingosine-1-phosphate 
SPK Sphingosine kinase 
TB Tuberculosis 
TDR-TB Totally-drug resistant tuberculosis 
TLRs Toll-like receptors 
VPS33B Vacuolar Protein Sorting 33B 
WHO World Health Organization 
XDR Extensively-drug resistant 
XDR-TB Extensively-drug resistant tuberculosis 
°C Degrees Celsius 
mg/mL Milligram per millilitre 
µg/mL Micrograms per millilitre 
pg/mL Picogram per millilitre 
µL Microliters 
w/w weight for weight 
w/v weight for volume 
% Percentage 
 
List of equations 
Equation 3.1            26 






List of tables 
Chapter 3 
Table 3.1. The varying % curdlan loads of each respective particle     26   
Table 3.2. The physico-chemical properties of the different C-PLGA NP formulations for both 
 the 1X wash and 2X wash methodologies        31 
Chapter 4 
Table 4.1. Strains and plasmids used in the study       37 
 
List of figures 
Chapter 1 
 
Figure 1.1. The subtle balance between LTBI and active TB disease    3  
Figure 1.2. The expected ligand-receptor interaction between curdlan and Dectin-1  5 
Chapter 2 
 
Figure 2.1. Timeline illustrating period (in years) between antibiotic discovery and resistance 
acquisition            13 
Figure 2.2. Overview of the major immune regulatory strategies exploited by M. tuberculosis  
within the macrophage          16 
Figure 2.3. Schematic representation of typical NP design for cellular targeted immune  




Figure 3.1. The single emulsion NP synthesis process      26 
Figure 3.2. The 12 different NP samples formulated and tested for induced cellular toxicity 
on RAW264.7 macrophages          29 
Figure 3.3. Experimental layout for MTT assay in a 96-well tissue culture plate   30 
Figure 3.4. Representative SEM images of PLGA NPs and 8% C-PLGA NPs confirming a  
spherical conformation          32 
Figure 3.5. MTT cytotoxicity assessment of different C-PLGA NP formulations administered  






Figure 4.1. Typical plate layout used to assess the growth inhibitory potential of C-PLGA NPs 38 
Figure 4.2. Effect of NPs on M. tuberculosis cell numbers over time    41 
Figure 4.3. MTT cytotoxicity assay with the 1X wash 8% C-PLGA NPs    42 
Figure 4.4. Assessing possible 1X wash NP toxicity-related cell lysis    43 
Figure 4.5. Determination of intracellular M. tuberculosis ΔleuDΔpanD::pMV306hsp-lux  
burden by CFU plating          44 
Figure 4.6. TNF-α cytokine secretion by RAW264.7 murine macrophages due to NP  
stimulation            45 
Figure 4.7. Luminescence expression of C-PCL NP treated intracellular M. tuberculosis  47 
Table of contents 
 
Declaration        ii 
Abstract                  iii 
Opsomming                  iv 
Acknowledgements                 v 
List of Publications                 vi 
List of Symbols and Abbreviations               vi 
List of Tables                  ix 
List of Figures                 ix 
Chapter 1 ................................................................................................................................................. 1 
General introduction............................................................................................................................... 1 
1.1 Background ................................................................................................................................ 1 
1.1.1 Tuberculosis and current therapeutic approaches ............................................................... 1 
1.1.2 Antibiotic resistance and tolerance ..................................................................................... 2 
1.1.3 Host-pathogen interaction and immune evasion ................................................................. 4 
1.1.4 Host directed therapeutic nanoparticles .............................................................................. 4 
1.2 Problem statement ...................................................................................................................... 5 




1.4 Aims and Objectives .................................................................................................................. 6 
Aim 1: To synthesize and characterize curdlan–functionalised PLGA (C-PLGA) NPs. ................. 6 
Aim 2: To determine the cytotoxicity of C-PLGA NPs on RAW264.7 macrophages. .................... 6 
Aim 3: To assess the ability of C-PLGA NPs to kill Mycobacterium tuberculosis within RAW264.7 
macrophages...................................................................................................................................... 6 
Aim 4: To characterize the stimulated immune response. ................................................................ 6 
1.5 Potential impact of the study ...................................................................................................... 6 
1.6 Thesis overview .......................................................................................................................... 7 
Chapter 2: Published literature review .............................................................................................. 7 
Chapter 3: Formulation and characterization of C-PLGA nanoparticles .......................................... 7 
Chapter 4: In vitro characterization of nanoparticle activity ............................................................ 7 
Chapter 5: Conclusion ....................................................................................................................... 7 
Chapter 6: References ....................................................................................................................... 7 
Chapter 2 ................................................................................................................................................. 8 
Literature review ..................................................................................................................................... 8 
2.1 Abstract ...................................................................................................................................... 9 
2.2 Introduction ................................................................................................................................ 9 
2.3 The mycobacteriology of Mycobacterium tuberculosis ........................................................... 10 
2.4 Current TB therapy and drug resistance ................................................................................... 11 
2.5 The interaction of M. tuberculosis with the macrophage and mechanisms of survival ........... 13 
2.5.1 Phagosome maturation and phagolysosome formation .................................................... 14 
2.5.2 Cytokine mobilization and granuloma formation ............................................................. 16 
2.6 The adaptive immune response to M. tuberculosis infection ................................................... 17 
2.6.1 Antigen presentation ......................................................................................................... 18 
2.6.2 T cell responses in adaptive immunity .............................................................................. 18 
2.6.3 Humoral immunity by B cells ........................................................................................... 19 
2.7 Immunotherapeutic NPs and M. tuberculosis eradication ........................................................ 19 
2.8 NP systems for vaccination against M. tuberculosis ................................................................ 20 
2.9 Summary and future directions ................................................................................................ 22 
2.10 Acknowledgments and disclosures ....................................................................................... 24 
Chapter 3 ............................................................................................................................................... 25 
Formulation and characterization of curdlan-functionalised poly(lactide-co-glycolide) 
nanoparticles.......................................................................................................................................... 25 




3.1.1. Consumables ..................................................................................................................... 25 
3.1.2. Equipment ......................................................................................................................... 26 
3.2 Methods .................................................................................................................................... 26 
3.2.1 Preparation of C-PLGA NPs. ............................................................................................ 26 
3.2.2 Characterizing the physiochemical properties of the C-PLGA NPs. ................................ 29 
3.2.3 Assessing the toxicity of C-PLGA NPs in RAW264.7 macrophages............................... 29 
3.2.5 Statistical analysis ............................................................................................................. 31 
3.3 Results and discussion .............................................................................................................. 32 
3.3.1 C-PLGA nanoparticle preparation and characterization ................................................... 32 
3.3.2 Cytotoxicity assay ............................................................................................................. 35 
3.4 Conclusion ................................................................................................................................ 37 
Chapter 4 ............................................................................................................................................... 38 
Characterization of Intracellular nanoparticle activity .................................................................... 38 
4.1. Materials ................................................................................................................................... 38 
4.1.1. Consumables ..................................................................................................................... 38 
4.1.2. Equipment ......................................................................................................................... 38 
4.2. Methods .................................................................................................................................... 39 
4.2.1. Bacterial strains and culture. ............................................................................................. 39 
4.2.2. Assessing the intracellular killing efficacy of C-PLGA NPs ............................................ 39 
4.2.3 Quantification of cytokines by multiplex luminex assay .................................................. 41 
4.2.4 Statistical analysis ............................................................................................................. 41 
4.3 Results and discussion .............................................................................................................. 41 
4.3.1 Assessing the intracellular killing efficacy of C-PLGA NPs ............................................ 41 
4.3.2 Cytokine quantification ..................................................................................................... 48 
4.4 Conclusion ................................................................................................................................ 50 
Chapter 5 ............................................................................................................................................... 52 
Conclusion, limitations and future recommendations ....................................................................... 52 
Supplementary material ....................................................................................................................... 55 
Chapter 3 ............................................................................................................................................. 55 
Chapter 4 ............................................................................................................................................. 57 
Published Literature review ................................................................................................................ 62 
Chapter 6 ............................................................................................................................................... 63 





Chapter 1  
General introduction 
The introductory chapter sets the tone for the rest of the thesis and highlights the need for novel 
therapeutic approaches against Tuberculosis. Chapter 1 also states the problem, contains the hypotheses 
as well as the aims and objectives on how we intend to achieve our goal. 
My contribution: Comprehensive search of relevant literature  
1.1 Background 
1.1.1 Tuberculosis and current therapeutic approaches 
Despite the widespread availability of various antibiotics, tuberculosis (TB) still poses a significant threat 
to global health. More than a century after Robert Koch identified Mycobacterium tuberculosis as the 
causative agent of TB, this bacterium is still classified as the deadliest infectious agent globally (Barberis 
et al., 2017; WHO, 2019). The World Health Organization (WHO) estimates that in 2017 alone, there 
were a reported 10 million cases of TB and that 1.6 million people passed away due to the disease (WHO, 
2018). An overwhelming 87% of all TB cases accounted for globally can be attributed to just 30 
countries. These countries include India (27%), China (9%), Indonesia (8%), the Philippines (6%), 
Pakistan (5%), Nigeria (4%), Bangladesh (4%) and South Africa (3%) (WHO, 2018). Notably, these high 
burden countries are predominantly located on continents infamous in large parts for overcrowding, 
poverty, poor nutrition and high levels of Human Immunodeficiency Virus (HIV) infections. The 
aforementioned issues are some of the key contributing factors related to higher TB incidence rates with 
the most influential element being HIV co-infection. People living with HIV have a 20-40 fold increased 
risk of developing TB compared to healthy individuals (Dheda et al., 2016). Consequently 464 633 of 
the reported cases in 2017 were amongst people living with HIV and the majority of these patients were 
already on antiretroviral therapy (WHO, 2018). Therefore, it is important that TB and HIV get treated as 
two sides of the same coin to ensure achievement of “End TB” strategies.  
The current standard treatment approach for susceptible TB consists of a regimen with four anti-TB drugs 
extending over a 6-month period. During the initial 2-month intensive phase patients take isoniazid 
(INH), rifampicin (RIF), ethambutol (EMB) and pyrazinamide (PZA) followed by a 4-month 
continuation period taking only INH and RIF (Tiberi et al., 2018). This regimen has been in use for 
around 30 years and according to the latest data collected on treatment outcomes, this regimen still proves 
to be effective with a global success rate of 82% in 2016. However, the treatment success rate drops to a 
mere 55% in the case of multi-drug resistant (MDR) and rifampicin resistant (RR)-TB infections (WHO, 
2018). Once antibiotic resistance is detected a patient no longer qualifies for the above mentioned shorter 
regimen and the standard treatment duration extends on average to around 18 months using at least 4 
active drugs (Louw et al., 2017; Tiberi et al., 2018). Medical practitioners will build a patient-specific 
regimen based on susceptibility test outcomes using a categorized list of second line antibiotics 
constructed by the WHO. The WHO recommends that the regimen contains a later-generation 




capreomycin, kanamycin) in combination with other core drugs such as ethionamide or prothionamide, 
cycloserine or terizidone, linezolid, and clofazimine (Tiberi et al., 2018). If further resistance is detected 
then non-core drugs can be added such as bedaquiline and delamanid, two of the most recently non-core 
drugs approved by the Food and Drug Administration (FDA) (2017) and common candidates within 
shorter anti-TB trials currently underway (Tiberi et al., 2018).  
Shorter regimens for the treatment of resistance TB have been evaluated extensively and until recently 
the “Bangladesh” regimen was the preferred approach consisting of 9 antibiotics administered over a 9-
12 month period. However, the STREAM trial compared the “Bangladesh” regimen with longer 
conventional resistant treatments and found that the shorter outdated “Bangladesh” regimen was non- 
inferior and showed similar toxicity than the longer regimens containing injectables (Seung and Hewison, 
2019). The aforementioned STREAM trial did not contain bedaquiline at that time and STREAM stage 
2 studies are currently in phase 3 of clinical trials, assessing a 6 and 9 month bedaquiline-containing 
regimen (RESIST-TB, 2019; Seung and Hewison, 2019). The effectiveness of bedaquiline has been 
reported on previously in a retrospective cohort study that compared drug resistant bedaquiline-
containing regimens with conventional regimens in South Africa and found that the addition of 
bedaquiline had an overall lower risk of mortality (Schnippel et al., 2018). Effectiveness of shorter 
bedaquiline-containing regimens are further supported by the NiX-TB study that have recently showed 
promising results for the use of bedaquiline in combination with pretomanid, and linezolid to treat 
extensively drug-resistant (XDR)-TB and MDR-TB patients within a 6 to 9 month period with regards 
to both efficacy and safety (RESIST-TB, 2019). Various other short regimen studies with and without 
bedaquiline are currently entering phase 3 of clinical trials including (RESIST-TB, 2019): i) TB-
PRACTECAL study (bedaquiline + pretomanid + existing and re-purposed anti-TB drugs), and ii) the 
ZeNix study (linezolid + bedaquiline + pretomanid).  
It is important to note that usage of these non-core drugs are kept to a minimum and drugs such as para-
aminosalicylic acid and carbapenems with clavulanate are only prescribed in the case of XDR-TB 
infections in an attempt to preserve drug efficacy and limit the acquisition of antibiotic resistance (Tiberi 
et al., 2018). Preservation of effective antibiotics is crucial since M. tuberculosis strains have been 
isolated that have shown resistance towards all know anti-TB antibiotics including bedaquiline; 
informally referred to as totally drug-resistant (TDR) strains (Louw et al., 2017). 
1.1.2 Antibiotic resistance and tolerance 
The low success rate of anti-TB regimens can to some extent be ascribed to i) genetically acquired and 
intrinsic antibiotic resistance as well as ii) phenotypically induced antibiotic tolerance (Torrey et al., 
2016). The prolonged prescription in combination with drug-induced negative side effects often leads to 
patients not adhering to their instructed regimen and in turn creates an environment that promotes the 
acquisition of resistance mutations (genetically acquired and intrinsic antibiotic resistance) (Gülbay et 
al., 2006; Louw et al., 2017; Nasiruddin et al., 2017). Antibiotic treatment over extended periods of time 
imposes strong selective pressure on M. tuberculosis. Selective pressure leads to the accumulation of 
independently acquired chromosomal mutations that render the bacilli drug resistant and aid in pathogen 
proliferation and transmission. M. tuberculosis forms highly clonal populations and is believed to solely 
transfer their de novo acquired mutations through bacterial division and not by horizontal gene transfer 
due to their lack of extrachromosomal plasmids (Zainuddin et al., 1990). In addition to acquired 




passive resistance through restricted cell wall permeation and more specialized mechanisms such as ii) 
the production of drug modifying and inactivating enzymes, iii) molecular mimicry, and iv) the presence 
of various efflux pumps (Smith  et al., 2013; Louw et al., 2017).  
M. tuberculosis is known to sporadically enter a phenotypically drug tolerant state (persister cells) in a 
stressful environment which is triggered by a downshift in metabolic processes (Gengenbacher et al., 
2012; Sikri et al., 2013; Prax et al., 2014). The ability to form persister cells is not a genetically inherited 
trait and is largely identified by a slow or non-growing population with a lower metabolic rate, a reduction 
in intracellular adenosine tri-phosphate (ATP) levels and an increase in lipid metabolism (Smith et al, 
2013; Mouton et al., 2016). These metabolically quiescent persister cells play a key role in clinically 
diagnosed latent TB infections (LTBI) characterized by an asymptomatic state and considered to be a 
major contributing factor in the relapse of TB disease (Zhang et al., 2014). Under control of an effective 
immune response the host can successfully maintain the bacilli in equilibrium in vivo and the persister 
population can survive for lengthy periods. Although persister cells can be widely localized within the 
host; generally, a granulomatous structure forms as a result of the delicate balance between host and 
bacterial factors and forms a visual representation of the pathological outcome of TB (Ndlovu et al., 
2016; Pagan et al., 2018). As long as the immune response can effectively contain the bacilli a person 
can remain asymptomatic; however, any reduction in immune efficacy will enable the persisters to revert 
back to actively replicating cells eventually tipping the equilibrium in favor of bacterial proliferation and 
the manifestation of active TB disease (Figure 1.1). Granuloma formation can be seen both as 
advantageous and unfavorable for the host since although the immune system can asymptomatically 
contain the bacilli for years it also actively restricts drug penetration (Barry et al., 2009) and acts as a 










Figure 1.1. The subtle balance between LTBI and active TB disease. The shift in the equilibrium 
between LTBI and active TB disease depends on the ability of the immune system to effectively contain 
the bacilli. Slight alterations in the efficacy of the immune system will tip the scale in favor of bacterial 
replication that will lead to active TB disease manifestation and eventual bacilli transmission. Image 
adapted from Delogu et al. (2013). 
The switch from complete eradication to mere containment is in part to blame on M. tuberculosis’ well 
evolved immune suppression mechanisms that inhibit the normal execution of stimulated bactericidal 
pathways (Pieters, 2008; Cambier et al., 2014; Weiss et al., 2015).  




1.1.3 Host-pathogen interaction and immune evasion 
Internalization of M. tuberculosis into macrophages initiates an immune response mediated through 
ligand-receptor interactions. Primary immune recognition cells bind to pathogen associated molecular 
patterns (PAMP’s), in particular mannosylated-lipoarabinomannan (Man-LAM), lipomannan (LM) and 
phosphatidylinositol mannoside (PIM), present on the bacilli through pathogen recognition receptors 
(PRR’s) such as Toll-like receptors, nucleotide oligomerization domain (NOD)-like receptors and C-type 
lectins (Kleinnijenhuis et al., 2011; Amaral et al., 2016). PAMP and PRR interactions activate various 
intracellular pathways that elicit context depended protective and pathological responses.  
Initial ligand-receptor interactions stimulate invagination and phagosome formation with the associated 
activation of intracellular bactericidal pathways. Important characteristics of these pathways include 
increased acidification and intracellular Ca2+ levels with high quantities of reactive oxygen and nitrogen 
species (ROS/RNS) and the secretion of various inflammatory cytokines and chemokines (Gengenbacher 
et al., 2012). Such specialized immune responses should theoretically be sufficient to control M. 
tuberculosis. However, these bacilli have successfully adapted to manipulate the host immune response 
to ensure survival and disease transmission. Although bacterial growth may be suppressed, these 
evolutionary adaptations prevent complete eradication by the immune system. Manipulation of the 
immune system occurs through mechanism that include masking of PAMP molecules, the exploitation 
of certain surface lipids that leads to the recruitment and uptake into growth permissive macrophages, 
and the secretion of molecules that prevent important maturation steps (Pieters, 2008; Cambier et al., 
2014; Weiss et al., 2015).  
1.1.4 Host directed therapeutic nanoparticles 
Advanced discoveries into host-pathogen interactions and stimulated immune pathways give us the 
insights necessary for the development of effective immunotherapeutic compounds that take a different 
approach to conventional treatment. Instead of targeting the pathogen directly, host directed strategies 
are aimed at the immune system, i.e. targeting cells such as macrophages, and the stimulation of a 
protective immune response thus reducing inflammation and tissue damage (Kolloli et al., 2017). The 
main challenge of host directed immunotherapy, especially with regards to TB, is to convert a 
bacteriostatic response resulting from successful immune inhibition back to a bactericidal protective 
response (Churchyard et al., 2009). Immunotherapeutic nanoparticles (NPs) have the potential to 
overcome ineffective immune responses by stimulating immune cell receptors and triggering an 
intracellular reaction. NPs are particulate (1–1000 nm) delivery systems whose surface can be 
functionalised with bioactive molecules (Figure 1.2) that enable them to modulate an immune response 
on the cellular level. Host directed therapy (HDT) NPs are an appealing alternative form of medicine due 
to their potential to avoid promoting the acquisition of resistance-causing mutations as the immune 
system is modulated and the bacilli are not the direct target (Tobin, 2015; Kolloli et al., 2017). 
Furthermore, they may support shortened treatment regimens (Dube et al., 2013).  
The NP core can be composed of a variety of materials and in this study we will exploit the high degree 
of biodegradability and biocompatibility of the polymer, poly(lactide-co-glycolide) (PLGA) (Makadia et 
al., 2011; Mei et al., 2015) to ensure the synthesis of non-toxic particles. Curdlan, a 1,3-β-glucan 
molecule, will be attached onto the surface of the PLGA NP to elicit immune stimulation (Figure 1.2). 




This ligand-receptor interaction stimulates a Syk/CARD9 signaling pathway that enhances phagocytic 
capabilities and the expression of pro-inflammatory genes as well as the increased production of 











Figure 1.2. The expected ligand-receptor interaction between curdlan and dectin-1. The 
synthesized NPs will be composed of a PLGA polymer core functionalised with the bioactive molecule 
curdlan. The curdlan will bind to the dectin-1 receptor on macrophages and stimulate various anti-
bacterial processes such as phagocytosis, production of pro-inflammatory cytokines and oxidative burst 
(Dube et al., 2013; Tukulula et al., 2015). 
Here, the synthesis and physio-chemical characterization of curdlan-functionalised PLGA particles are 
reported on as well as the assessment of their anti-bacterial efficacy using a murine macrophage cell line 
containing Mycobacterium tuberculosis. Results obtained through this study will form the groundwork 
for more in depth-characterization assays necessary to fully assess NP function and efficacy.  
1.2 Problem statement 
Mycobacterium tuberculosis remains a deadly infectious agent, responsible for significant mortality 
worldwide. Although a variety of anti-TB drugs are widely available, treatment success is complicated 
by the ability of the bacilli to suppress protective immune responses. Further, the necessity for a lengthy 
treatment regimen with undesirable side-effects, frequently leads to patients being non-compliant and 
exacerbates the problem of antibiotic resistance. There is therefore an urgent need for alternative 
treatments for TB. Host directed therapeutic NPs show promise as an effective treatment strategy for TB, 
since surface functionalization incorporates cell specificity and the desired stimulated immune response 
that can bypass resistance mechanisms employed by the bacterium.  
1.3 Hypotheses  
It is hypothesized that the introduction of curdlan-functionalised PLGA nanoparticles to M. tuberculosis 





1.4 Aims and Objectives 
Aim 1: To synthesize and characterize curdlan–functionalised PLGA (C-PLGA) 
NPs.  
Curdlan-functionalised poly(lactide-co-glycolide) nanoparticles (C-PLGA NPs) will be synthesized 
using a single emulsion evaporation technique (Shim et al., 2006; McCall et al., 2013; Sirianni et al., 
2013; Yadav et al., 2016). The NPs will be functionalised with different amounts of curdlan, i.e. 2%, 5% 
and 8% (w/w) and a control with no curdlan will be included. The physicochemical properties of the NPs 
(size, polydispersity index and zeta potential) will be characterized through dynamic light scattering 
(DLS) analysis and the surface morphology will be determined by scanning electron microscopy (SEM).  
Aim 2: To determine the cytotoxicity of C-PLGA NPs on RAW264.7 
macrophages. 
The 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay will be 
used to assess the toxicity of the different NPs in the murine macrophage cell line, RAW264.7. NP 
toxicity will be assessed using three different NP concentrations of 1 mg/mL, 2.5 mg/mL and 5 mg/mL. 
In total twelve NP samples will be tested.  
Aim 3: To assess the ability of C-PLGA NPs to kill Mycobacterium tuberculosis 
within RAW264.7 macrophages.  
The killing efficacy of the NPs (at a concentration proven to be non-toxic), will be assessed on M. 
tuberculosis-containing macrophages. RAW264.7 macrophages will be infected with a double leucine 
and pantothenate auxotrophic M. tuberculosis strain (M. tuberculosis::ΔleuDΔpanD) encoding the 
LuxABCDE gene. LuxABCDE gene expression allows for auto-luminescence of the bacilli and enabling 
use of luminescent readings as a real time proxy for cell numbers. The macrophages will be infected with 
M. tuberculosis at an MOI of 10:1 after which the NPs will be introduced to the macrophages and 
luminescence will be tracked over a 3 day period using a microplate reader.  
Aim 4: To characterize the stimulated immune response.  
A customized mouse Multiplex cytokine assay will be performed to determine the cytokine expression 
profile induced by the NPs. A cytokine panel consisting of three pro-inflammatory and three anti-
inflammatory cytokines relevant to TB that include TNF-α, IFN-γ, IL-12, IL-4, IL-10, and IL-1β will be 
assessed (Kleinnijenhuis et al., 2011; Dube et al., 2013) . 
1.5 Potential impact of the study 
The results of this study will provide insights into the possible application of immunotherapeutic NPs in 
the eradication of M. tuberculosis. In future, this could lead to the discovery of a novel anti-TB therapy. 
By elucidating the immune response elicited through NP administration we can gain a comprehensive 




response necessary for pathogen clearance. Additionally, it can provide us with the knowledge about NP 
surface functionality and the required adaptions to stimulate an optimal target-specific (either pathogen 
or tissue type) response.  
1.6 Thesis overview 
Chapter 2: Published literature review 
Mycobacterium tuberculosis and Interactions with the Host Immune System: Opportunities for 
Nanoparticle Based Immunotherapeutics and Vaccines. 
Briefly, the review covers host-pathogen interactions, the elicited immune response and the well-
developed immune evasion strategies employed by M. tuberculosis to overcome such responses. In 
addition to immune evasion we specify the shortcomings of current conventional approaches against TB 
and indicate where the use of host directed NPs can be exploited and applied and how nanomedicine can 
overcome these shortcomings. Finally, the review closes with a comprehensive overview of current NP-
based therapeutics already in use and highlights the knowledge gaps and future prospects. 
Chapter 3: Formulation and characterization of C-PLGA nanoparticles 
This Chapter describes the synthesis and characterization of NPs. Particle characterization including size, 
polydispersity index (PDI) and zeta potential data was obtained using dynamic light scattering (DLS) 
techniques. The surface morphology was established using scanning electron microscopy (SEM) image 
analysis. An MTT cytotoxicity assay of the NP formulations was performed on RAW264.7 macrophages 
to investigate the applicable safety of these particles.  
Chapter 4: In vitro characterization of nanoparticle activity 
This Chapter describes studies to evaluate the ability of NPs to inhibit the growth of intracellular M. 
tuberculosis in RAW264.7 macrophages infected with a luminescent M. tuberculosis strain. 
Luminescence will be tracked over a 3 day period to assess changes in bacterial cell numbers. 
Additionally, cytokine expression due to particulate macrophage stimulation is assessed by conducting 
a mouse Multiplex cytokine assay. Customized panels include TNF-α, IFN-γ, IL-12, IL-4, IL-10, and IL-
1β. By quantifying these analytes insights will be gained into the inflammatory response elicited by the 
C-PLGA NPs.  
Chapter 5: Conclusion 
In the final Chapter all the results are taken together and the significance of what was discovered is 
discussed, shortcomings highlighted and future prospects mentioned. Altogether, the results point to the 
potential of C-PLGA NPs to be applied in the treatment of TB, although further investigation is 
necessary.   






This Chapter represents a published review (reformatted to fit within the thesis) which provides an 
overview of the interaction that occurs between M. tuberculosis and the macrophage and highlights the 
immune response elicited through such interactions. Furthermore, it addresses the shortcomings of 
current anti-TB therapeutics and highlights the various adaptive mechanisms used by M. tuberculosis to 
successfully manipulate the host immune system. This highlights where NPs can be exploited as a 
possible treatment approach and how nanomedicine can overcome the shortcomings of current treatment 
against TB and possibly other intracellular infections such as Human immunodeficiency virus (HIV). 
The review highlights current knowledge and applications of NPs as treatment for infectious diseases, 
their application as a possible vaccine approach and what lies ahead for nanomedicine in the future.  
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2.1 Abstract 
Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a deadly infectious disease. The thin 
pipeline of new drugs for TB, the ineffectiveness in adults of the only vaccine available, i.e. the Bacillus 
Calmette-Guerin vaccine, and increasing global antimicrobial resistance, has rein vigorated interest in 
immunotherapies. Nanoparticles (NPs) potentiate the effect of immune modulating compounds (IMC), 
enabling cell targeting, improved transfection of antigens, enhanced compound stability and provide 
opportunities for synergistic action, via delivery of multiple IMCs. In this review we describe work 
performed in the application of NPs towards achieving immune modulation for TB treatment and 
vaccination. Firstly, we present a comprehensive review of M. tuberculosis and how the bacterium 
modulates the host immune system. We find that current work suggest great promise of NP based 
immunotherapeutics as novel treatments and vaccination systems. There is need to intensify research 
efforts in this field, and rationally design novel NP immunotherapeutics based on current knowledge of 
the mycobacteriology and immune escape mechanisms employed by M. tuberculosis. 
Keywords. immunotherapeutic nanoparticles; immunotherapy for tuberculosis; Mycobacterium 
tuberculosis; nanoparticle based host directed therapy; nanoparticles and vaccination 
2.2 Introduction 
Tuberculosis (TB) remains a deadly infectious disease. In 2017, about 10 million people became ill with 
TB and there were 1.6 million deaths from this disease. Over 60% of cases arose from seven countries 
with India leading the count, followed by Indonesia, China, The Philippines, Pakistan, Nigeria and South 
Africa (WHO, 2017). Worldwide, about 1.7 billion people are estimated to be living with asymptomatic 
TB infection. To underscore the seriousness with which governments consider this pandemic, in 
September 2018, a high level United Nations General Assembly meeting was held with the goal of 
discussing unified approaches to ending TB pandemic by the year 2035 (Amani, 2018; Fauci, 2018)). 
TB is primarily acquired following inhalation of aerosolized Mycobacterium tuberculosis (M. 
tuberculosis) bacilli and the majority of TB cases are pulmonary in nature (WHO, 2017). Drug treatment 
of TB is intensive, requiring daily intake of a cocktail of ‘first-line’ antibiotics for at least 6 months to 
achieve a cure. In cases where M. tuberculosis has become resistant to the drugs isoniazid (INH) and 
rifampicin (RIF) (known as multi-drug resistant tuberculosis (MDR-TB)), treatment using ‘second-line’, 
more toxic drugs which include injectables, for up to 18 months is required (Tiberi et al., 2018). The 
increasing global incidence of MDR-TB (defined as resistance to a fluoroquinolone and one injectable 




towards the development of new drugs with novel mechanisms of action to avoid generation of drug 
resistant M. tuberculosis strains. However, despite these efforts, drug resistance remains un-curtailed and 
more severe forms of resistance known as extensively drug resistant tuberculosis (XDR-TB) have been 
detected (Abate et al., 2016; WHO, 2017). 
M. tuberculosis is primarily an intracellular pathogen and the macrophage is the major host cell (Amaral 
et al., 2016). The bacterium possess an innate ability to suppress the antimicrobial response of the 
macrophage. The survival strategies of M. tuberculosis within macrophages, which are detailed in this 
review, primarily involve prevention of phagosome maturation and an attenuation of pro-inflammatory 
responses (Kusner, 2005; Dube et al., 2016).The current body of knowledge of the survival strategies 
employed by M. tuberculosis within the immune system, coupled with decreasing effectiveness of 
conventional antibiotics and a rise in drug resistant strains has led to revived interest in developing 
immunotherapies for TB. Within this context, immunotherapies encompass approaches in which 
compounds with immune modulating activity are administered in order to ‘activate’ immune cells to 
become a hostile environment for intracellular M. tuberculosis. A number of immune modulating 
compounds (IMCs) are at various stages of development and range from lipids and polysaccharides, 
cytokines and drugs such as metformin and albendazole (Guler et al., 2015; Abate et al., 2016). 
Engineered nanoparticles (NPs) have been employed to effectively deliver IMCs to immune cells and 
this application is discussed further in this review. 
Vaccination is one of the most effective strategies for disease prevention. Unfortunately, the only vaccine 
available against M. tuberculosis, i.e. the Bacillus Calmette-Guerin (BCG) vaccine, has very limited 
effect against adult pulmonary TB (Khademi et al., 2018). Therefore, developing novel, effective 
vaccination strategies alongside new treatment modalities is a promising strategy to eradicate TB 
globally. Numerous vaccine candidates for TB are currently in the clinical trial pipeline (Frick, 2015). 
However, most vaccines do not show strong immunogenicity and lack innate ability to be delivered to 
appropriate sites for optimal immune stimulation. In this regard, NPs are being applied to achieve 
optimum induction of robust innate and adaptive immune responses and to target antigens to immune 
cells and facilitate transfection and this is discussed later. 
The goal of this review is to stimulate intensified research to develop immunotherapeutic NPs for TB 
treatment and vaccination. To facilitate the reader’s entry into this field, we firstly provide a 
comprehensive review of M. tuberculosis and how it modulates the host innate and adaptive immune 
systems. We then describe current work on the application of immunotherapeutic NPs towards M. 
tuberculosis eradication and vaccination. 
2.3 The mycobacteriology of Mycobacterium tuberculosis 
In 1882 Robert Koch successfully isolated and identified M. tuberculosis as the causative agent of TB 
(Cambau et al., 2014). M. tuberculosis is one of more than a hundred closely related species within the 
genus Mycobacterium. This genus is divided into two groups, i.e. non-tuberculous mycobacteria that are 
made up of non-pathogenic or opportunistic, fast-growing pathogens including M. smegmatis and the M. 
tuberculosis complex comprising mainly of slow growing, disease-causing species such as M. leprae and 
M. tuberculosis (Forrellad et al., 2013; Sinha et al., 2016). M. tuberculosis is a gram-variable, contagious 
rod shaped pathogen varying in diameter and length between 0.3–0.5 μm and 1.5–4.0 μm, respectively 




and can readily switch from a carbohydrate to a fat diet in an attempt to adjust to the evolving host cell 
conditions (Cook et al., 2009) 
M. tuberculosis is surrounded by a characteristically thick and waxy cell envelope containing 
interconnected polymers of mycolic acids (MAs), arabinogalactan (AG) and peptidoglycan (PG) 
(Niederweis et al., 2010; Rodriguez-Rivera et al., 2017). This unique envelope renders M. tuberculosis 
hydrophobic; a trait primarily attributed to the presence of the MAs which are long chain fatty acids of 
up to 90 carbon atoms in length (Marrakchi et al., 2014). The hydrophobic membrane acts as a 
permeability barrier towards various hydrophilic and lipophilic compounds making M. tuberculosis 
inherently resistant to antibiotics (Hett et al., 2008; Niederweis et al., 2010; Merget et al., 2013; 
Rodriguez-Rivera et al., 2017). However, the inherent resistance cannot solely be attributed to the 
impermeable membrane since experiments have shown that drugs are able reach cytotoxic levels within 
cells (Hett et al., 2008). This stresses the important contribution of other virulence factors such as efflux 
pumps and drug degrading enzymes towards the intrinsic resistance of M. tuberculosis (Hett et al., 2008; 
Niederweis et al., 2010; Louw et al., 2017). 
An additional pathway in which M. tuberculosis proves to be problematic towards the cure of TB, is its 
ability to enter a non-replicating persistent (NRP) state enabling it to survive within the host until 
conditions are more favourable (Hett et al., 2008; Gengenbacher et al., 2013). Persister cells are a simple 
descriptive term used for tubercle bacilli within the NRP state and these cells are phenotypically and 
reversibly tolerant towards antibiotics (Mouton et al., 2016). Most conventional antibiotics are designed 
to target cellular functions important for microbial growth and proliferation in actively replicating cells. 
However, NRP cells are thought to be metabolically quiescent characterised by a thickening of cell walls, 
a decrease in protein synthesis and transcription rates, and a low metabolic state with ATP levels up to 
5-fold lower compared to actively replicating cells (Rittershaus et al., 2013). This automatically 
eliminates common antibiotic targets which renders these cells tolerant towards various antibiotics if they 
remain within the NRP state. Only a small number of bacterial cells enter the NRP state and Keren et al. 
(2004) reported that the persister fraction of an inoculum exposed to antibiotics was only around 1%. 
This low generation frequency together with their transient nature is the reason knowledge of persister 
cells is limited and the exact mechanisms by which they enter and exit this state is still unclear (Lewis, 
2010). Various factors are alleged to induce persister cell formation including presence of an acidic 
environment, growth-limiting by-products such as acetate and nutrient and oxygen depletion (Wayne et 
al., 2001). Persisters are believed to be the cause of latent TB infections (LTBI) that is defined by a non-
contagious, clinically asymptomatic state (Mouton et al., 2016). Approximately 5–10% of persons 
infected with M. tuberculosis will eventually develop primary active TB and 90–95% will remain latently 
infected, not because the bacilli gets eradicated but is effectively controlled within granulomatous 
structures (Gideon et al., 2011). LTBI is a major obstacle in the control of TB due to the chance of disease 
activation once the cells exit the NRP state and proliferate. Consequently, latently infected persons are 
the pool of future infections. The possibility of persister cells being present ensures that anti-TB treatment 
regimens extend over long periods of time aggravating an already rigorous antibiotic course. 
2.4 Current TB therapy and drug resistance 
Treatment is administered as a ‘cocktail’ of several antibiotics, each targeting various mycobacterial 
functions at relatively high doses as a preventative measure against acquisition of resistance. Treatment 




ethambutol and pyrazinamide) during the initial 2-month intensive phase (Tiberi et al., 2018). The course 
for drug-resistant TB extends to around 18 months of 4 core drugs (later-generation fluoroquinolone such 
as moxifloxacin, an injectable aminoglycoside such as amikacin plus ethionamide or prothionamide, 
terizidone or cycloserine, linezolid and clofazimine) with an intensive phase of at least 8 months. 
Elevated doses of the antibiotics are used and cause severe side effects including ototoxicity, 
hepatotoxicity, hyperuricemia and neuropsychiatric problems (Gülbay et al., 2006). The current lengthy 
treatment regimens and side effects are a major cause of patient non-compliance and consequently failure 
of TB treatment and the manifestation of drug resistance (Abate and Hoft, 2016). 
M. tuberculosis rapidly acquires resistance to antibiotics (Figure 2.1) and it is estimated that this rate is 
similar for both bacterial cells in both active and NRP state. Therefore it is proposed that mycobacterial 
mutations occur in a time-dependent manner instead of a replication dependent manner (Rittershaus et 
al., 2013). Contrary to most bacterial species, resistance is not attributed to horizontal gene transfer and 
is completely reliant on independently acquired chromosomal mutations and non-chromosomal events 
such as the production of drug modifying and inactivating enzymes, along with the presence of a MA-
rich membrane and efflux pumps (Smith et al., 2013; Louw et al., 2017). Fitness costs frequently 
accompany these resistance mutations through secondary mutations on different loci; however, M. 
tuberculosis remains fully virulent and successfully fixes resistance mutations in consecutive populations 
(Smith et al., 2013). 
The contribution of antibiotic resistance towards the TB epidemic has led to the restricted use of the most 
recently discovered anti-TB drugs (i.e. bedaquiline and delamanid) to retain efficacy and to maintain low 
levels of resistance. Clinical studies are also on-going to optimize use of existing TB drugs by 





Figure 2.1.Timeline illustrating period (in years) between antibiotic discovery and resistance 
acquisition. The brackets list the mode of action of the antibiotic and the primary genes involved in 
acquired resistance to the specific antibiotic. Image adapted from Calitz et al. (unpublished). 
2.5 The interaction of M. tuberculosis with the macrophage and 
mechanisms of survival 
M. tuberculosis is primarily transmitted via inhalation of aerosolized bacilli and establishes infection 
within the lung. Bacilli are detected by resident immune cells including alveolar macrophages, dendritic 
cells (DCs) and neutrophils. An innate immune response is initiated through selective binding to pattern 
recognition receptors (PRRs) such as Toll-like receptors (TLRs), C-type lectin receptors (CLRs), and 
Nod-like receptors (NLRs) (Opitz et al., 2013; Amaral et al., 2016). 
PRRs recognize polysaccharide-like structures present on M. tuberculosis known as pathogen associated 
molecular patterns (PAMPs), specifically mannosylated-lipoarabinomannan (Man-LAM), lipomannan 
(LM) and phosphatidylinositol mannoside (PIM) (Amaral et al., 2016). PAMP motifs are highly 
conserved within species and are used as unique identifiers of an invading pathogen. The fate of ingested 
M. tuberculosis in immune cells can alternate between complete eradication, latent containment within a 





2.5.1 Phagosome maturation and phagolysosome formation 
PAMP recognition of PRRs leads to phagocytic uptake of M. tuberculosis by macrophages (MPs) (Silva 
Miranda et al., 2012). Engagement of PRRs initiates formation of pseudopod-like structures around the 
bacterium that seal at the tips and form an intracellular vesicle known as a phagosome (Levin et al., 
2016). The subsequent maturation stages are characterised by fusion of the phagosome with various 
endosomal and lysosomal compartments that alters its protein and enzymatic composition and initiates 
the desired antimicrobial activity. Key stages include the early phagosome, late phagosome and eventual 
formation of the phagolysosome (Levin et al., 2016). 
M. tuberculosis can successfully prevent phagosome maturation and persist within vesicles characterised 
by continuous association with Rab5, the absence of PI3P and sphingosine kinase (SPK), low V-ATPase 
levels, a near neutral pH, and the active retention of coronin-1. Early phagosomes fuse with early 
endosomes and acquire Rab5, which recruits the hVPS34 kinase that together with other molecules, leads 
to the cyclic accumulation of PI3P on the phagosomal membrane. PI3P is a membrane trafficking 
regulatory lipid believed to be an important docking site for various proteins specifically the early 
endosomal antigen 1 (EEA1) and the class C core vacuole/endosome tether (CORVET) complex; these 
are central role players in membrane fusion and the ensuing phagosome maturation and phagolysosome 
formation stages (Chua et al., 2004; Pieters, 2008; Pauwels et al., 2017). 
However, reports have shown that PI3P is absent on the phagosomal membranes containing live M. 
tuberculosis but is continuously present on those that harbour dead cells (Jayachandran et al., 2007). M. 
tuberculosis prevents accumulation of PI3P through direct interference with the hVPS34 kinase 
responsible for PI3P production or through the secretion of SapM, a PI3P hydrolysing enzyme 
(Jayachandran et al., 2007; Pieters, 2008). The transition from an early phagosome to a late phagosome 
is characterised by replacement of Rab5 with Rab7, the acquisition of lysosomal enzymes delivered in 
transport vesicles and the accumulation of lysosome-associated membrane proteins (LAMP1 and 2) 
necessary for phagolysosome formation (Weiss et al., 2015). The late phagosome becomes a more 
hydrolytic and oxidative compartment suited for cargo degradation. Rab7 is important for centripetal 
movements and mediates the switch from a CORVET complex to the homotypic fusion and vacuole-
sorting (HOPS) complex important for late endosomal fusion (Levin et al., 2016; Pauwels et al., 2017). 
M. tuberculosis produces PtpA, a protein tyrosine phosphatase, which dephosphorylates and inactivates 
the host protein Vacuolar Protein Sorting 33B (VPS33B), a regulator of membrane fusion. Inactive 
VPS33B cannot generate GTP-activated Rab7 hence blocking phagosome maturation and PL fusion 
(Pieters, 2008; Weiss et al., 2015; Levin et al., 2016; Pauwels et al., 2017). 
Following M. tuberculosis ingestion, V-ATPase is rapidly recruited to the phagosomal membrane 
gradually acidifying the intraphagosomal compartment through inward pumping of protons (H+) 
(Pauwels et al., 2017). M. tuberculosis selectively excludes V-ATPase from the phagosomal membrane 
and arrests the internal acidification process at a pH of approximately 6.4; much higher than the intended 
pH (≤ 5) of the late phagosome necessary for downstream functioning of various phagosomal proteases 
and lysosomal enzymes (Gengenbacher et al,, 2012; Weiss et al., 2015; Queval et al., 2017). Exactly 
how M. tuberculosis excludes V-ATPase is an ongoing debate, but Queval et al. (2017) demonstrated 
possible strategies M. tuberculosis exploits to target the V-ATPase complex. Their studies have shown 
that the CISH protein is actively recruited to M. tuberculosis containing phagosomes and actively leads 




et al. (2011) also showed a direct link between PtpA and its ability to bind directly to the H subunit of 
the V-ATPase complex. Binding to the unit actively prevents the trafficking of this enzyme to M. 
tuberculosis -containing phagosomes. A low pH in mature phagosomes is important to ensure optimal 
enzymatic functioning of degrading lysosomal enzymes such as cathepsin D that are delivered once the 
phagosome fuses with the lysosome. 
Calcium (Ca2+) mobilization is associated with microbial ingestion. Increases in cytosolic Ca2+ levels are 
marked by the binding of Ca2+ with calmodulin (CaM) that activate CaMKII (Malik et al., 2003; Kusner, 
2005). This signalling cascade leads to the activation of hVPS34 that catalyses PI3P production and the 
consequent binding of EEA1 to PI3P, promoting membrane fusion and phagosome maturation (Kusner, 
2005). Firstly, M. tuberculosis can suppress sphingosine kinase (SPK) therefore blocking the increase in 
macrophage cytosolic Ca2+ levels (Malik et al., 2003). Macrophage ingestion of inactivated M. 
tuberculosis cells activates SPK resulting in the translocation of the enzyme to the phagosome membrane. 
SPK phosphorylates sphingosine, yielding sphingosine-1-phosphate (S1P) that induces an increase in 
Ca2+ from endoplasmic reticulum (ER) stores (Malik et al., 2003). Secondly, in contrast to the prior 
mentioned inhibiting effects, M. tuberculosis can also effectively exploit the increase in Ca2+ levels to 
prolong survival. M. tuberculosis actively retains coronin-1 on the phagosomal membrane leading to the 
Ca2+dependent activation of calcineurin and consequently, the direct prevention of phagosome-lysosome 
fusion (Jayachandran et al., 2007). Notably, Jayachandran et al. (2007) showed that coronin-1 dependent 
Ca2+ mobilization is independent of SPK. This might be due to the differences observed in internalization 
between opsonized and non-opsonized M. tuberculosis which activates different downstream signalling 
pathways. 
The final stage of bacterial destruction is the fusion of the late phagosome with lysosomal compartments 
mediated by various soluble NSF attachment protein receptors (SNAREs) (Pauwels et al., 2017). The 
resulting phagolysosome becomes acidic (pH 4.5) and the degradative capacity is enhanced through 
acquisition of various hydrolytic enzymes such as cathepsin (Weiss et al., 2015; Pauwels et al., 2017). 
At this stage antimicrobial effects are further elevated through an increased production of reactive oxygen 
and nitrogen species (ROS/RNS) augmented by the NADPH oxidase (NOX) complex, recruited to the 
phagosome membrane throughout the maturation process, and the inducible nitric oxide synthase (iNOS) 
(Gengenbacher et al., 2012; Levin et al., 2016; Pauwels et al., 2017). NOX, in particular NOX2, transfers 
electrons from NADPH to intra-phagosomal oxygen forming superoxide anions. These anions dismutate 
to form hydrogen peroxide and other toxic ROS. In addition, iNOS generates nitrate and nitrite that reacts 
with nitrous acid at a low pH producing nitric oxide and nitrogen dioxide. Nitric oxide and superoxide 
radicals can finally come together and form the highly toxic peroxynitrite (Gengenbacher et al., 2012). 
These reactive radicals are important for pathogen eradication; however, M. tuberculosis can avert 
toxicity through the production of proteins involved in detoxification and damage repair. The primary 
strategy employed by M. tuberculosis is the secretion of KatG, a catalase-peroxidase that catabolizes 
peroxides within the phagosome (Pieters, 2008; Gengenbacher et al., 2012). Oxidative stress can be 
further subdued by LAM which can scavenge free oxygen radicals (Gengenbacher et al., 2012). In 
addition, to inhibit phagolysosome fusion, M. tuberculosis secretes PknG, a eukaryotic homolog and 
kinase acting protein, into the cytosol of the macrophage. PknG phosphorylates a currently unknown host 
molecule that acts as a mediator in membrane fusion hence suppressing lysosomal delivery of the 
phagosome by the host factor (Pieters, 2008). Figure 2.2 summarizes the major immune regulatory 





Figure 2.2. Overview of the major immune regulatory strategies exploited by M. tuberculosis 
within the macrophage. The bacilli can prolong its survival by actively preventing maturation and fusion 
of the M. tuberculosis-containing phagosome characterised by continuous association with Rab5, 
absence of PI3P, low V-ATPase levels hence a near neutral pH, the active retention of coronin-1 on the 
membrane, and a decrease in cytosolic Ca2+ levels due to SPK suppression. In addition, M. tuberculosis 
can secrete various proteins including SapM, PtpA, PknG and KatG acting on various stages of the 
maturation and fusion steps. The mycobacterial polysaccharide, LAM, can directly inhibit IFN-γ 
secretion. Moreover, M. tuberculosis-containing macrophages secrete higher levels of IL-10, a major 
negative regulator of macrophage activation. IL-10 production inhibits IL-12 secretion and consequently 
suppresses IFN-γ production. 
2.5.2 Cytokine mobilization and granuloma formation  
Uptake of M. tuberculosis by macrophages leads to secretion of various cytokines and chemokines. These 
cytokines and chemokines act in concert and lead to increased vascular permeability, mediate systemic 
effects such as fever and the recruitment of various inflammatory cells (Duque et al., 2014). The 
macrophage cytokine profile is made up of pro-inflammatory cytokines including IFN-γ, TNF-α, IL-2, 
IL-6, IL-12, IL-18, IL-23 and anti-inflammatory cytokines IL-27 as well as IL-4, IL-10, IL-13 and TGF-
β (Duque et al., 2014; Wang et al., 2014). The different cytokine groups activate different macrophage 
phenotypes differentiating between a degrading pro-inflammatory macrophage with a Th1 cell cytokine 
environment or a macrophage phenotype characterised by a “resting” state with low microbicidal effects 
and a Th2 cytokine profile (anti-inflammatory). Macrophage activation through pro-inflammatory 
cytokines is necessary to obtain effective bactericidal properties. However, it is important that these pro-
inflammatory cytokines are produced in appropriate amounts to prevent cytotoxic effects within the host. 




tuberculosis LAM inhibits IFN-γ secretion, an important macrophage activating cytokine (Meena et al., 
2010). In addition to LAM, internalization of M. tuberculosis induces an increased production of IL-10, 
an anti-inflammatory cytokine associated with IFN-γ suppression. O’Leary et al. (2011) reported that 
macrophages infected with live M. tuberculosis secreted approximately 2X more IL-10 in comparison to 
macrophages infected with dead/inactivated M. tuberculosis. Addition of an anti-IL-10 antibody led to 
enhanced phagosome maturation highlighting the importance of IL-10 in mycobacterial pathogenicity 
and survival (O’Leary et al., 2011). An increased production of IL-10 leads to the decreased production 
of IL-12 and reduced recruitment of macrophage activating cytokines (O’Leary et al., 2011; Dube et al. 
2016). By successfully inhibiting macrophage activation, M. tuberculosis consequently arrests the 
phagosome maturation process as well as the subsequent degradative pathways. 
Cytokine and chemokine production leads to the recruitment of various cell populations to the site of the 
M. tuberculosis-containing macrophages including epithelioid cells, Langhans giant cells, mononuclear 
phagocytes, fibroblasts, and T and B lymphocytes (Gengenbacher et al., 2012; Silva Miranda et al., 
2012). These immune regulatory cells form a highly organised structure known as a granuloma. Necrotic 
macrophages are generally located within the center of the granulomatous structure surrounded by 
interconnected layers of multinucleated giant cells, apoptotic macrophage, foam cells, dendritic cells, 
and neutrophils (Pagan et al., 2018). The outermost layer of the structure is surrounded by a layer of T 
cells, B cells, and natural killer cells known to be major producers of IFN-γ and recognize specific 
peptides bound to major histocompatibility complexes (Pagan et al., 2018). The granuloma is a hallmark 
of most M. tuberculosis infections and creates an immune micro-environment that enables the host to 
control the infection, mediated by a fine balance between pro- and anti-inflammatory cytokine 
production. TNF-α and IFN-γ are considered to be important pro-inflammatory cytokines involved in the 
functioning and formation of the granuloma with IL-10 being the major negative regulator (Silva 
Miranda et al., 2012). In 90–95% of infected patients, the subsequent formation of a solid granuloma is 
a telling sign that the immune system is effectively containing M. tuberculosis and the bacilli in general 
enters the NRP state resulting in a latent, asymptomatic infection. Should the cytokine balance be tipped, 
the bacilli may reactivate, forming caseous lesions and the development of active symptomatic TB 
(Gengenbacher et al., 2012). The likelihood of this balance being disrupted in favour of active disease 
development increases for patients with compromised immune systems as in the case of human 
immunodeficiency virus (HIV) co-infection. Once the balance is tipped, the granuloma becomes 
increasingly necrotic, characterised by caseation, eventually leading to the active transmission of M. 
tuberculosis bacilli (Silva Miranda et al., 2012).  
2.6 The adaptive immune response to M. tuberculosis infection  
Despite the initial attempt to eliminate the bacilli by cells of the innate immune system, prolonged host 
protection from active disease requires the generation of adaptive immune response that are initiated and 
driven by the activated antigen presenting cells (APCs), i.e. macrophages and dendritic cells (DCs) (Wolf 
et al., 2008; Harari et al., 2011). The coordination between innate and adaptive immune responses is 
comprised of cellular, cytokine and chemokine components which are necessary for effective control of 




2.6.1 Antigen presentation 
Antigen presentation by APCs is a crucial step that links the innate and adaptive immunity and involves 
distinctive mechanisms. For major histocompatibility complex (MHC) class II presentation, M. 
tuberculosis peptide antigens are presented by APCs to antigen-specific CD4+ T cells, which are thought 
to be the most important protective response for control of intracellular infection (Caruso et al., 1999). 
For MHC-I presentation, all nucleated cells are able to present M. tuberculosis peptide antigens to 
antigen-specific CD8+ T cells. This mechanism allows infected cells with cytosolic peptide antigens to 
be killed through Fas/Fas-L induced apoptosis or granule-mediated function (Canaday et al., 2001). The 
stimulation of T cells in the context of MHC molecules activates adaptive immunity and induces IFN-γ 
secretion and cytolytic CD8 T cell activity. However, as described earlier, M. tuberculosis employs 
several evasion strategies to circumvent the phagosome-lysosome fusion pathway, and thereby prevents 
antigen processing and presentation to T cells. 
Unlike macrophages, DCs are considered professional APCs and act as initiators of specific T cell 
immunity against M. tuberculosis infection (Tallieux et al., 2003; Prendergast et al., 2013). Depletion of 
DCs delays onset of M. tuberculosis specific CD4+ T cells priming that compromises host immunity in 
conjunction with uncontrolled bacilli replication (Tian et al., 2005). After bacilli uptake, DCs present 
antigens to T cells following migration to the draining lymph node in an IL-12 and TNF-α dependent 
manner. Upon arrival in lymph nodes, DCs become functionally mature, characterized by upregulation 
of MHC-II, CD40, CD80, and CD86, to effectively stimulate naïve T cells (Khader et al., 2006; Keeton 
et al., 2014). Although a complex regulatory process, TNF-α is known to be an important factor that 
facilitates DC maturation towards specific T cell priming (Caux et al., 1992; Sallusto et al., 1994). 
Interestingly, while persistent TNFRp55 expression leads to potential defective T cell responses during 
chronic M. tuberculosis infection (Dambuza et al., 2016), sustained TNF-α expression by DCs enhances 
maturation and generates a much more robust T cell response (Zhang et al., 2003). Thus, DCs are 
positioned to serve as an important link between innate and adaptive immunity and may act as useful 
targets for immunotherapy and vaccine development (Griffiths et al., 2016; Ahmad et al., 2017). 
2.6.2 T cell responses in adaptive immunity 
The adaptive immune response is initiated in the peripheral lymphoid organs, and consists of cell-
mediated immunity by T cells and humoral immunity by B cells. Research in the area of immunity to M. 
tuberculosis has largely focused on T cells due to their critical role in the elimination of bacteria during 
primary infection, followed by their ability to generate M. tuberculosis specific and memory responses 
to protect from subsequent infections. The importance of CD4+ T cells against M. tuberculosis is 
supported by the clinical association of increased susceptibility to TB in HIV infected patients (Selwyn 
et al., 1989; Lahey et al., 2013). This is supported by murine studies with antibody depletion of CD4+ T 
cells or the use of gene-deficient mice (Caruso et al., 1999; Scanga et al., 2000), which show that the 
loss of CD4+ T cells significantly increases susceptibility to M. tuberculosis infection. Following 
priming, synthesis of IL-2 promotes naïve T cell proliferation and differentiation into different subsets 
of effector T cells, particularly CD4+ Th1 cells and type 1 cytokine responses that are crucial for 
protection against M. tuberculosis. The major effector function of CD4+ T cells is considered to be the 
production IFN-γ which is pivotal for host protection. The critical role of IFN-γ in M. tuberculosis 
infection was demonstrated in various experimental studies (Cooper et al., 1993; Flynn et al., 1993) and 




M. tuberculosis -specific CD4+ T cells has been explored for its use as a biomarker for diagnosis of 
active TB disease (Harari et al., 2011). The contribution of T cell derived TNF-α to immune defense 
against M. tuberculosis has been investigated using T cell-specific TNF-α deficient mice and shown that, 
while myeloid TNF-α is required for initial control of bacterial replication, T cell-derived TNF-α is 
essential to sustain protection during chronic TB infection (Dongowski et al., 2012). Interestingly, in 
contrast, TNF-α from T cells was found to be largely redundant in cerebral immunity against TB infection 
(Hsu et al., 2017). 
2.6.3 Humoral immunity by B cells  
It is generally accepted that while cell-mediated immune response is the effector branch of adaptive 
immunity to defend intracellular pathogens, the extracellular counterparts are protected by the humoral 
immune response, in which B cells are activated to secrete antibodies. Like T cell responses, the antibody 
responses are antigen specific and have different ways to mediate the clearance of pathogens, such as 
neutralization and opsonization. Although the understanding of adaptive immune response against M. 
tuberculosis relies pre-dominantly on the studies of cell-mediated immunity, increasing evidence 
supports the role of B cell and humoral immunity in the defense against M. tuberculosis infection (Chan 
et al., 2014; Achkar et al., 2015). Serological detection tests indicate that M. tuberculosis infection 
induces humoral immune responses to a wide variety of mycobacterial antigens (Steingart et al., 2009). 
Studies have also shown that the BCG vaccine can elicit antibody responses to various mycobacterial 
antigens (Brown et al., 2003; De Vallière et al., 2005), and contribute to immune protection against 
mycobacteria. Moreover, in vitro and animal studies using antibodies to M. tuberculosis antigens have 
shown enhanced protection with increased survival and reduced bacterial burden (Pethe et al., 2001; 
Williams et al., 2005). Recent immunization studies with mycobacterial capsular arabinomannan 
conjugates have demonstrated antibody and T cell responses that contribute to protective immunity 
against M. tuberculosis (Prados-Rosales et al., 2017). These findings provide evidence for the potential 
role of humoral immunity in TB vaccine development strategies. 
2.7 Immunotherapeutic NPs and M. tuberculosis eradication  
NPs have been used to stimulate macrophages to achieve eradication of intracellular M. tuberculosis. 
Greco et al. (2012) developed an immunotherapeutic liposome comprised of phosphatidylserine (PS) on 
the outer membrane and phosphatidic acid (PA) in the inner membrane (Janus faced liposomes). PS was 
included in the NP design to inhibit cellular production of pro-inflammatory cytokines and enhance anti-
inflammatory cytokine secretion. PA is a lipid IMC involved in phagolysosome maturation (Greco et al., 
2012). Hence the strategy was to achieve M. tuberculosis killing using PA and avoid the pathology 
associated with over production of pro-inflammatory cytokines using PS. From the same research group, 
Poerio et al. (2017) synthesized similar liposomes having PS in the outer layer, however, additional lipids 
in the inner layer were investigated for ability to lead to mycobacterial killing, i.e. PA, PI3P, 
phosphatidylinositol 5-phosphate (PI5P), lysobisphosphatidic acid (LBPA), S1P and arachidonic acid 
(AA). These lipids were selected due to their known ability to promote phagosome maturation (Poerio et 
al., 2017). 
Greco et al. demonstrated that the presence of PA on the liposomes enhanced intracellular mycobacterial 
(M. tuberculosis H37Rv) killing in THP-1 macrophages and in human bronchoalveolar lavage cells 




et al., 2012). Further, the desired balance in the immune response was demonstrated. Production of pro-
inflammatory cytokines IL-1β, IFN-γ and TNF-α was dampened, while TGF-β production was enhanced. 
Similarly, Poerio et al. demonstrated enhanced phagosome acidification (to a pH of up to 5.5) when 
PS/PA, PS/ PI3P and PS/PI5P NPs were incubated with BCG infected THP-1 macrophages. These NPs 
also promoted ROS production and ultimately enhanced mycobacterial killing in macrophages (Poerio 
et al., 2017). 
Intranasal administration of the PS/PA liposomes to M. tuberculosis infected BALB/C mice was shown 
to result in a 100-fold reduction in pulmonary bacterial burden after 4 weeks, in comparison to a 2-fold 
reduction from orally administered INH. Combined administration of the PA liposomes and INH also 
proved effective. A tenfold reduction in serum levels of TNF-α, IL-1β and IFN-γ was observed with PA 
liposome treatment alone or in combination with isoniazid (Greco et al., 2012). These studies 
demonstrate that cellular induction of phagosome maturation and ROS production, while suppressing 
pro-inflammatory cytokine secretion is a viable strategy to killing intracellular mycobacterium species. 
NPs in this instance allowed co-delivery of the IMCs to macrophages, allowing presentation of one type 
of IMC (i.e. PS) to the macrophage surface receptors and the presentation of multiple IMCs within the 
macrophage. 
An IMC functionalised polymeric NP was developed by Dube et al. (Dube et al., 2013). The 
polysaccharide IMC, i.e. 1,3-β-glucan, was adsorbed onto the chitosan shell and the NP core comprised 
the polymer poly(lactide-co-glycolide) (PLGA). RIF was also loaded into the NP core, and could be 
released in a sustained manner. 1,3-β-glucan activates dectin-1 on macrophage surfaces subsequently 
activating various downstream signal transduction pathways which promote pro-inflammatory gene 
expression as well as intracellular ROS/RNS production. Pro-inflammatory cytokines known to be 
produced through Dectin-1 activation include IL-12 (Chan et al., 2009; Goodridge et al., 2009). Apart 
from gene induction, Dectin-1 signalling also increases intracellular Ca2+, following phosphorylation of 
various intracellular phospholipases (Xu et al., 2009)(Xu et al., 2009). Given these pharmacological 
effects, Dectin-1 activation by 1,3-βglucan can potentially reverse the immune suppressive effects of M. 
tuberculosis in MPs. A significant increase of IL-12p70, TNF-α, INF-γ and ROS were reported, 
following incubation of these NPs with healthy human alveolar-like macrophages. Levels of anti-
inflammatory cytokines IL-4 and IL-10 remained unchanged (Dube et al., 2013). In later work, linear 
chain 1,3-β-glucan, i.e. curdlan, was chemically conjugated onto PLGA producing IMC functionalised 
PLGA polymer which could form NPs (Tukulula et al., 2015). The curdlan-PLGA NPs could stimulate 
THP-1 macrophages as evidenced by enhanced phosphorylated ERK production, an upstream mediator 
of ROS/RNS. These studies demonstrate the stimulation of APCs using β-glucan functionalised NPs, 
however, further studies in M. tuberculosis infected cells are required, as well as studies to determine an 
acceptable balance between macrophage activation secretion and bacterial killing. Recently, Hwang et 
al. (2018) conjugated single stranded β-glucan onto silica NPs. These NPs also encapsulated INH which 
could be released in a sustained manner. However, these NPs were observed to minimally activate 
peripheral blood mononuclear cell (PBMCs) as both the silica NPs and INH loaded silica/ glucan NPs 
stimulated the PBMCs at similar levels to control (Hwang et al., 2018). 
2.8 NP systems for vaccination against M. tuberculosis  
Various NP based vaccine candidates have been evaluated in animal models and show encouraging 




pluronic-stabilized sulphide NPs. The NPs alongside the immuno-stimulatory oligonucleotide CpG were 
delivered to mice and it was demonstrated that vaccination with NP-Ag85B via the pulmonary route 
substantially reduced lung bacterial burden (Ballester et al., 2011). These findings therefore suggest that 
pulmonary immunization with NPs can serve as an effective strategy for the design of future TB vaccines. 
There is a sufficient evidence to prove that in comparison to other sites, mucosal vaccination via the 
respiratory tract provides improved immune protection against pathogenic bacteria (Chen et al., 1995; 
Giri et al., 2006). However, mucosal adjuvants are challenged with respect to ability to generate robust 
cellular immune responses via this route which has curtailed their progression to the clinic (Stylianou et 
al., 2014). The induction of immune responses by mucosal immunization requires the co-administration 
of appropriate adjuvants that can initiate and support the effective collaboration between innate and 
adaptive immunity (Belyakov et al., 2009). BCG-primed mice were shown to have an enhanced immune 
response following intranasal delivery of Ag85B-HBHA (heparin binding hemagglutinin adhesion 
protein) by carnauba wax NPs (Stylianou et al., 2014). BHA is a mycobacterial protein utilized by M. 
tuberculosis to achieve adherence to alveolar epithelium (Pethe et al., 2001) and this property was 
exploited by linking to the highly immunogenic and protective Ag85B (Kaufmann, 2000; Langermans 
et al., 2005; Gartner et al., 2008). Human clinical trials were performed demonstrating that Ag85B and 
early secretory antigen target (ESAT-6) adjuvanted with IC31 could generate long-lasting Th1 cell 
responses (van Dissel et al., 2010; van Dissel et al., 2011). Additional work to deliver Ag85B and ESAT-
6 using liposomes (CAF01) as adjuvant was performed in humans. CAF01 is a liposome composed of 
dimethyldioctadecyl-ammonium stabilized with a glycolipid immunomodulatory trehalose 6,6-
dibehenate which is a synthetic variant of cord factor located in the mycobacterial cell wall. The vaccine 
system has been demonstrated to be safe and efficacious in humans (Hussein et al., 2018). Clinical testing 
of this formulation is ongoing. 
To enhance the magnitude of the immune response, Yu et al. (2012) applied Fe3O4-glutamic acid-
polyethyleneimine (PEI) NPs as a delivery system to co-deliver Ag85A with ESAT-6 of M. tuberculosis 
and IL-21.The results indicated that the NP based vaccine induced a strong immune response (in 
comparison to administration of Ag85A-ESAT-6-IL-21 alone) and significantly reduced growth of M. 
tuberculosis in the lungs of mice. The authors attributed the enhanced immune response to improved 
cellular delivery and consequent transfection by the NPs (Yu et al., 2012). 
One of the more common materials that have been used for vaccine delivery is PLGA (Kirby et al., 2008; 
Carlétti et al., 2013; Rose et al., 2015) In one example, Bivas-Benita et al. (2009) loaded the TB antigen 
Rv1733c onto the surface of PLGA-PEI NPs. Intratracheal intubation of the NPs led to enhanced T cell 
responses. These NPs were able to stimulate and induce maturation of DCs (evidenced by up-regulation 
of surface expression of the molecules CD40, CD80, CD83 and CD86 in culture) and IFN-γ induction in 
mice. Liposomes have also been recognized as efficient immunoadjuvants and delivery systems 
(O’Hogan et al., 2003; Khademi et al., 2018). A peptide DNA-liposome conjugated vaccine was 
investigated by Rosada et al. (2008). By entrapping DNA-hsp65 vaccine within cationic liposomes, these 
particles could elicit a strong Th1 pattern of immune response (following intranasal administration) that 
resulted in bacilli reduction and lung preservation in mice (Rosada et al., 2008). The use of liposomes 
significantly reduced the amount of DNA-hsp65 vaccine required (16 fold reduction) while maintaining 
optimum levels of immune response. In the first decade of 2000’s, Okada et al. reported 100% survival 
in non-human primate model of TB (Cynomolgus monkey) when administered with BCG plus DNA-
hsp65 vaccine encapsulated in liposomes (Okada et al., 2007). However, there has been no indication of 




Researchers from South Africa have advanced an NP vaccine formulation to clinical trials, i.e. a synthetic 
nanoemulsion adjuvant, GLA-SE (a synthetic TLR-4 agonist glucopyranosal lipid adjuvant) formulated 
in an oil-in-water emulsion and further adjuvanted with TB antigen ID93 (Penn-Nicholson et al., 2018). 
Based on the reproducible efficacy and enhanced Th1 response exhibited by the ID93/GLA-SE 
formulation, clinical trials to estimate safety and immunogenicity in humans are underway, and recent 
reports of the Phase I clinical trial indicate very promising results (Penn-Nicholson et al., 2018). The 
reader is also directed to Khoshnood et al. (2018) for a comprehensive review of novel vaccine candidates 
for TB currently at various stages of pre-clinical and clinical evaluation (Khoshnood et al., 2018). 
2.9 Summary and future directions  
It is encouraging that one of the major global funders of TB biomedical research the United States 
National Institute of Allergy and Infectious Diseases (NIAID) recently released a research plan towards 
ending the TB epidemic (Fauci, 2018), which also describes the need to conduct research to improve 
fundamental knowledge of bacterial biology and host immune mechanisms that eliminate or control the 
bacterium. These research activities are seen as part of the components of a toolkit for development of 
host-directed therapies, less toxic drug regimens, new diagnostic tools and vaccines. 
To date, limited work has been performed on the application of immunotherapeutic NPs to achieve 
intracellular eradication of M. tuberculosis. Much more work has been performed to apply NPs as 
delivery systems and adjuvants to achieve effective vaccination, and it is exciting that at least one 
candidate is currently undergoing clinical evaluation (Penn-Nicholson et al., 2018). An 
immunotherapeutic NP can have the design of the immunomodulating compounds (IMC) encapsulated 
within the NP core (providing opportunity for compound protection and controlled release), or 
incorporated within the NP shell (Figure 2.3). Janus faced NPs are particularly interesting in this regard, 
as they enable different IMC presentation to various parts of the cells over time (Greco et al., 2012). The 
IMCs could also be chemically conjugated onto the surface of the NP (Tukulula et al., 2015) and such 
conjugation could be achieved through linkers to provide triggered release of the IMC, e.g. under certain 
pH, enzyme or redox conditions. Conjugation will enable precise insight of the amount of IMC delivered 
to the immune cells; which may prove beneficial in cases where fine tuning of the immune response is 
required to mitigate toxicity. Using NPs, combination immunotherapy has been described (Greco et al., 
2012) and multiple IMCs or an IMC and an antibiotic (Dube et al., 2013) can be delivered to cells with 
higher efficiency compared to compound delivery in the absence of the NP. 
Looking to the future, it is our opinion that studies to evaluate several other types of NPs and IMCs for 
intracellular TB eradication are required. Future studies should include more mechanistic and 
immunological assessments in order to gain understanding of NP and immune cell interactions and cell 
activation processes, NP elimination pathways and kinetics. Rational selection of materials for NP 
synthesis and IMCs will be required and some of the general NP design considerations presented in 





Figure 2.3. Schematic representation of typical NP design for cellular targeted immune 
modulation for TB treatment and vaccination. The IMC may be conjugated onto the particle and 
remains an intrinsic part of the NP (integration of immune functionality into the NP). The IMC may also 
be conjugated onto the surface of the NP via linker which allows release under specific conditions. The 
rate (k1) of release of the IMC can be controlled through linker selection. The IMC may in both cases 
bind to specific receptor located on target cell surface. The IMC may also be loaded in the core of the 
NP and released at a controlled rate (k2) and bind to surface receptors or enter cell and interact with 
intracellular receptors or proteins. 
The efficacy of NP immunotherapy approaches to eradicate intracellular M. tuberculosis within the 
granulomatous structure remains to be shown. Existing in vitro granuloma as well as animal models 
could be used to determine efficacy in this clinically relevant scenario. Typically, in immunotherapy, 
macrophages have been the target, however, DCs could also be targeted, as they are positioned as a link 
between the innate and adaptive immunity and thus can act as useful targets for both therapy and 
vaccination. Toxicity is a concern which should be addressed. Some authors have used combination 




of the macrophage. This is an interesting approach which should be looked into further with the aim of 
striking a balance between toxicity and efficacy. TB typically occurs in the context of HIV coinfection. 
Hence pre-clinical and clinical studies to evaluate these therapies and vaccination approaches should 
consider the HIV co-infection scenario. For example, how immune activation may lead to immune 
reconstitution inflammatory syndrome. 
Currently, the field of cancer immunotherapy is an area of intense exciting research offering many 
possibilities for disease treatment. Researchers in infectious disease immunotherapy could derive lessons 
from the cancer field to drive this emerging field at a faster rate towards the clinic. Indeed, from early 
stages, research in this field requires global partnerships of multidisciplinary teams involving at least 
microbiologists, immunologists, material scientists and pharmaceutical scientists. We believe that NP 
immunotherapies hold the key to highly effective and safe TB treatments and vaccinations. We hope that 
research in this field will become intensified in the near future. 
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Formulation and characterization of curdlan-functionalised 
poly(lactide-co-glycolide) nanoparticles 
Chapter 3, which is presented in manuscript format, describes the synthesis and characterization of 
poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) functionalised with varying ratios of curdlan 
(2%, 5% and 8% (w/w)). This work forms part of a larger study, and the characterization of the physico-
chemical properties of the NPs was also conducted by Ms. Raymonde Bekale and Dr. Sarah D’Souza at 
the University of the Western Cape (UWC). In this Chapter, the toxicity of the NPs are examined on 
RAW264.7 murine derived macrophages using the (3- (4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. The 4 different NP formulations are applied in three different 
concentrations of 1, 2.5 and 5 mg/mL. This will highlight the applicable safety of the NPs for further 
intracellular treatment assays.  





The following solvents and reagents were used for the synthesis of the NPs: 
Poly(D-L-lactide-co-glycolide) with a lactide:glycolide ratio of 50:50 (PLGA, MW 30-60 kDa), curdlan 
(origin: Alcaligenes faecalis, MW 189 kDa)), poly vinyl alcohol (PVA; MW, 13–23 kDa) and sucrose 
were all obtained from Sigma-Aldrich. The two solvents, dichloromethane (DCM) and dimethyl 
sulfoxide (DMSO) were purchased from Laborem and Merck, respectively. All the reagents and solvents 
were of analytical grade and used as instructed by supplier unless stated otherwise. 
The following cell line and reagents were used for assessing toxicity: 
RAW264.7 murine macrophages (ATCC TIB-71) cultured in D10 (Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) both of which were obtained from 
ThermoFisher) and the passage number continuously maintained below 30. Phosphate-Buffered Saline 
(PBS) were obtained from ThermoFisher and the MTT (3- (4,5-dimethylthiazol-2-yl)-2,5-








The following equipment was used: 
Analytical balance (Mettler®, model PE 6000); Stuart magnetic stirrer (Staffordshire, UK); QSONICA 
Probe sonicator (QSONICA); BÜCHI Rotary evaporator (BÜCHI, Labotec); Eppendorf 5804 Benchtop 
Centrifuge (Marshall Scientific); Bath sonicator (SCIENTECH, Labotec); Upright ultralow -80 °C 
freezer (NU-9668E, NuAire); Freeze dryer (Virtis, Freeze mobile model 125L); Malvern Zetasizer 
NanoZS90 (Malvern); Sputter coater (Emitech K550X); Scanning electron microscope (Auriga HR-SEM 
F50, Zeiss); Thermo Steri-Cycle CO2 incubator (Marshall Scientific), FLUOstar Omega plate reader 
(BMG LABTECH).  
3.2 Methods 
3.2.1 Preparation of C-PLGA NPs. 
Four different NP formulations were prepared by means of regulating the mass ratio of the C-PLGA co-
polymer (containing 10% w/w of curdlan on the C-PLGA NP) mixed with the pure PLGA polymer 
(Tukulula et al., 2015). The C-PLGA co-polymer was obtained from the laboratory of Prof. Dube at 
UWC following conjugation of curdlan to PLGA using a published protocol with 10% w/w curdlan 
particles (Tukulula et al., 2015). The amounts (mg) of PLGA polymer and C-PLGA co-polymer that 
were weighed to synthesize the NPs containing the desired amounts of curdlan (2%, 5% and 8% (w/w)) 
were determined using Equation 3.1 and are presented in Table 3.1. PLGA only NPs were also included 
as the fourth formulation. The desired NP formulations were decided on in an attempt to investigate a 
wide enough range of curdlan loads. The maximum load of curdlan synthesized were 8% w/w C-PLGA 
and beyond 8% the co-polymer becomes difficult to dissolve within a solvent necessary for NP synthesis. 
Thus a range between 0 and 8% w/w curdlan were chosen.  
 
𝑆𝑡𝑒𝑝 1:  % 𝐶𝑢𝑟𝑑𝑙𝑎𝑛 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 =
𝐶­𝑃𝐿𝐺𝐴 𝑚𝑎𝑠𝑠 (𝑚𝑔) × 10% 
20 𝑚𝑔 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑝𝑜𝑙𝑦𝑚𝑒𝑟
 







Table 3.1. The varying % curdlan loads of each respective particle. The desired curdlan content on 
the NP surface was achieved by blending the various masses of C-PLGA co-polymer with PLGA 





The single emulsion-evaporation technique, with adaptions from Shim et al. (2006), McCall et al. (2013), 
Sirianni et al. (2013), and Yadav et al. (2016) was used to synthesize the C-PLGA NPs (Figure 3.1). 
These fundamentally include use of sucrose as cryoprotectant (Shim et al., 2006) and finding the ideal 
parameters under which the PLGA NPs should be synthesised and characterised, as discussed below 
(McCall et al., 2013; Sirianni et al., 2013 and Yadav et al., 2016). Briefly, to synthesize the NPs, amounts 
of C-PLGA and PLGA were weighed according to the calculated masses (Table 3.1) and were dissolved 
in DMSO and DCM, respectively, using a probe sonicator to ensure complete dissolution. The two 
solutions were combined in a glass vial under magnetic stirring (1500 rpm), and thereafter added 






Mass ratio of 
PLGA:C-PLGA 
 PLGA C-PLGA 
0% (PLGA only) 20 mg 0 mg 
2% 16 mg 4 mg 
5% 10 mg 10 mg 






















Figure 3.1. The single emulsion NP synthesis process. A) Chemical structure of PLGA and a 
diagrammatic depiction of the polymer. B) Chemical structure of the C-PLGA co-polymer and a 
diagrammatic depiction thereof. The chemical structure highlights the binding site between curdlan and 
the PLGA polymer to form the resulting C-PLGA co-polymer. C) Illustration depicting the first few steps 
in the synthesis process and the diagrammatic representation of the resulting C-PLGA NP. Adapted 
from Tukulula et al. (2015). 
The resultant emulsion was transferred into a round bottomed flask and the organic solvents (DMSO, 
DCM) were removed through evaporation in a rotary evaporator (BÜCHI RII) (35ºC, 20 minutes). The 
resulting NPs were collected by centrifugation (10 000 rpm, 20 minutes) and washed either once (1X 
wash) or twice (2X wash) with distilled water in an ultrasonic bath (10 minutes, intensity 5) 
(SCIENTECH, Labotec). Both 1X and 2X wash NPs are reported on with the 1X wash NPs likely 
containing more residual PVA compared to the 2X wash NPs. Sucrose (1% w/v) was added to the final 
volume as a cryoprotectant and the NPs were lyophilized over a 2 day period. The final product was 




3.2.2 Characterizing the physiochemical properties of the C-PLGA NPs. 
The lyophilized NPs were resuspended in distilled water (1 mg/mL) using an ultrasonic bath (10 minutes, 
intensity 5) (SCIENTECH, Labotec) and the suspension transferred into disposable 12 mm square 
polystyrene cuvettes. A Malvern NanoZS was used to measure the size and polydispersity index (PDI) 
of the NP suspension within the cuvette at a 90° scattering angle using dynamic light scattering (DLS) 
principles at 25 °C. DLS is a non-invasive technique that determines NP size based on the speed by which 
the particles move within a suspension due to Brownian motion. The smaller the particle, the quicker the 
Brownian motion and vice versa (Stetefeld et al., 2016). Together with the size and PDI measurements, 
the NanoZS was also used to analyze the zeta potential of the NP suspension. Averages of triplicate 
repeats were reported for all the above-mentioned characterization steps. Scanning electron microscopy 
(SEM) was used to assess the morphology of the NPs. The NP pellet was smeared on an aluminium stub 
with a carbon adhesive and left in a fume cupboard overnight to dry at room temperature. The dry pellet 
was coated with a thin film of palladium at 40 mA for 1 minute using a sputter coater and then observed 
under the microscope.  
3.2.3 Assessing the toxicity of C-PLGA NPs in RAW264.7 macrophages 
Macrophage (RAW264.7) viability after C-PLGA NP exposure was measured using the MTT assay; a 
calorimetric assay frequently used for the assessment of drug toxicity towards host cells. The assay 
exploits the ability of metabolically active eukaryotic cells to reduce the thiazolyl blue tetrazolium salt 
into water insoluble formazan crystals. The amount of crystals formed correlates with cell metabolism. 
Reduction occurs predominantly through the actions of dehydrogenase enzymes as well as other lesser 
known reducing agents such as ascorbic acid and cysteine (Stockert et al., 2012; Riss et al., 2017). The 
addition of DMSO dissolves the formazan crystals, forming a violet-blue color with an absorbance 
maximum near 570 nm. Absorbance values were translated into cell survival measurements and 
expressed as percentage cell viability relative to untreated controls (Equation .2).  
 
% 𝒄𝒆𝒍𝒍 𝒗𝒊𝒂𝒃𝒊𝒍𝒊𝒕𝒚 =  
𝑶𝑫 𝒐𝒇 𝒕𝒓𝒆𝒂𝒕𝒆𝒅 𝒘𝒆𝒍𝒍𝒔
𝑶𝑫 𝒐𝒇 𝒖𝒏𝒕𝒓𝒆𝒂𝒕𝒆𝒅 𝒘𝒆𝒍𝒍𝒔
× 𝟏𝟎𝟎  
Equation 3.2 
 
3.2.3.1 Nanoparticle preparation 
Each of the four different NP formulations were introduced in three different concentrations of 1 mg/mL, 
2.5 mg/mL and 5 mg/mL to the macrophages. In total, 12 different NP samples were prepared and used 
for in vitro cytotoxicity evaluation (Figure 3.2). The NPs were weighed in 1.5 mL eppendorf tubes, 
dispersed in sterile D10 (Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) 
heat-inactivated fetal bovine serum) and probe sonicated (QSONICA, Newton, USA) to ensure complete 
dispersion of the NPs (1 minute; 50% power). The NP solutions were UV sterilized for 30 minutes before 








Figure 3.2. The 12 different NP samples formulated and tested for induced cellular toxicity on 
RAW264.7 macrophages. The particle range consisted of the PLGA NPs (0% w/w curdlan) and C-
PLGA NPs containing 2%, 5% and 8% w/w curdlan. Each of the final samples was tested at three 
different concentrations ([NP]) on the macrophages of 1 mg/mL, 2.5 mg/mL and 5 mg/mL in 
quadruplicate technical repeats. 
3.2.3.2 MTT cytotoxicity assay 
RAW264.7 (ATCC TIB-71) cells were seeded at 2.5×104 cells per well within a black, clear bottom, 96-
well tissue culture plate containing 100 µL D10. Cells were cultured within plates for 24h at 37 °C, 5% 
CO2 before the NPs were added. The media was replaced with 50 µL of fresh D10 and 50 µL of the 
desired NP formulation suspended in D10 and thereafter incubated at 37 °C, 5% CO2 for a further 24h, 
48h and 72h, respectively. Each NP formulation was added at the three different NP concentrations and 
each concentration was tested in quadruplicate (Figure 3.3). NP toxicity was assessed on the 2X wash 



























Figure 3.3. Experimental layout for MTT assay in a 96-well tissue culture plate. The plate was 
replicated for the three different time points and analyzed on each respective day. NP concentrations 
were tested in technical quadruplicates and 3 biological replicates were performed for each experiment 
performed. A p value ≤ 0.05 were considered to be statistically significant between the different 
treatments.  
On the day of the assay, the cells were washed once with PBS and 100 µL of the fresh MTT solution was 
added to the treated wells and incubated for 4h at 37 °C, 5% CO2. The MTT solution was dissolved in 
PBS (5 mg/mL) and filter-sterilized (2 µm) to remove contaminants as well as undissolved MTT clumps. 
Following the incubation period, the MTT solution was replaced with 200 µL DMSO and absorbance 
was read at 570 nm using a microplate analyzer. Cytotoxicity was tested over a 3 day period and a 
microplate was sacrificed on each respective day. Toxicity was assessed in quadruplicate technical 
repeats and three biological repeats. The absorbance values obtained were translated into percentage (%) 
cell viability as explained through Equation .1. This provided an indication of percentage cell viability 
relative to the untreated control over time for each of the treatment formulations.  
3.2.5 Statistical analysis 
DLS and MTT data were analysed using GraphPad Prism v7.05 and expressed as the mean ± standard 
deviation (n=3). Differences between the means were analysed by performing a One-way analysis of 
variance (ANOVA) and a Two-way ANOVA for the DLS and MTT data, respectively. Observable 
differences were considered to be statistically significant if the calculated p-value was less than 0.05. If 
a statistically significant difference was identified, a Post hoc test was performed to specify between 










3.3 Results and discussion 
3.3.1 C-PLGA nanoparticle preparation and characterization 
As a first step in this study, PLGA NPs and C-PLGA NPs containing varying curdlan content (2%, 5% 
and 8% (w/w)) were successfully synthesized. This was achieved by effectively controlling the ratios of 
C-PLGA co-polymer to PLGA polymer during the synthesis process. Following NP synthesis, a series 
of analytical techniques were used to characterize the particles, and confirm that they possessed the 
desired characteristics.  
To assess particle size, Dynamic light scattering (DLS) data were obtained using the Malvern NanoZS 
(Table 3.2; Figure S3.1, S3.2). In general, it was found that the size of the NPs was not influenced by 
the amount of wash steps involved and that the average NP size remained relatively similar throughout, 
although 1X wash NPs were predicted to be more stable in suspension given their higher average zeta 
potential values.  
Table 3.2. The physico-chemical properties of the different C-PLGA NP formulations for both the 
1X and 2X wash methodologies. Data represents triplicate repeats presented as mean ± standard 
deviation. Samples were analysed using a Malvern Zetasizer NanoZS90 at 25 ˚C. A one-way ANOVA 
was conducted on each of the different parameters followed by a Tukey's multiple comparisons test and 
a P < 0.05 considered to be statistically significant. *Indicate a statistically significant difference.  
 1X Wash 2X Wash 
Nanopartic
le 
DH (nm) PDI Zeta 
potential 
(mV) 
DH (nm) PDI Zeta 
potential 
(mV) 
 Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
PLGA 335.9±9.1 0.21±0.04 -20.9±2.3 339.0±12.4 0.25±0.01 -21.9±4.3 
2%  
C-PLGA 
354.9±21.2* 0.28±0.06* -21.3±0.4 360.4±30.0 0.25±0.04 -22.4±7.5* 
5%  
C-PLGA 
293±33.3* 0.21±0.04 22.2±2.2  313.7±14.5* 0.28±0.04 -18.2±5.8 
8%  
C-PLGA 
290.5±11.2* 0.16±0.01* -23±1.7 380.1±26.6* 0.34±0.07 -6.7±6.0* 
 
For the 1X wash NPs, the mean hydrodynamic diameter (nm) was found to be between 290.53 ± 11.2 
nm and 354.9 ± 21.2 nm with a significant difference observed between the 2% C-PLGA and 5% C-
PLGA NPs (P=0.028) as well as the 2% C-PLGA and 8% C-PLGA NPs (P= 0.023). For the 2X wash 
NPs a size range between 313.7 ± 14.5 nm and 339.0 ± 12.4 nm was observed with a significant difference 
between occurring between the 5% C-PLGA and 8% C-PLGA NPs (P= 0.026). A two-ANOVA was 
used to analyze the differences in the physico-chemical properties between the 1X wash and 2X wash 
and a Sidak’s multiple comparisons test indicated that the only significant difference was for the 8% C-
PLGA NP; size (P=0.0004), PDI (P=0.0006), zeta potential (P=0.0014). These findings correspond with 
previously published literature on NPs designed and tested for macrophage-specific stimulation 
(Tukulula et al., 2015; Abdelghany et al., 2019). Tukulula et al. (2015, 2018) designed curdlan-




encapsulated glucan-PLGA NPs ranging between 264.3 ±4.6 nm and 301.2 ± 5.5 nm (2015) as well as 
260.5 ± 12.4 nm and 283.1 ± 7.0 nm (2018). In both of these studies the authors showed that the NPs 
were effectively taken up by macrophages and that a macrophage-specific immune response was indeed 
stimulated. Furthermore, Abdelghany et al. (2019) synthesized and tested PLGA NPs and alginate-
entrapped PLGA NPs loaded with moxifloxacin and amikacin with a size range between 294 ± 2.3 nm 
and 347 ± 21 nm. Similar to the findings of Tukulula et al. (2018), these antibiotic loaded particles were 
effectively taken up by macrophages and the antibiotics released within. The optimal size for macrophage 
uptake is still heavily debated, but it is suggested that particulate phagocytosis occurs more rapidly for 
NPs with an intermediate size average around 200 nm (Sharma et al., 2010; Fenaroli et al., 2014). 
Interestingly, PLGA NPs within this intermediate size average have been shown to localize within 
macrophages and in the lungs of mice once administered intravenously at the tail (Fenaroli et al., 2014). 
A possible explanation for the preferential intermediate size might be an evolutionary adaption from the 
host. Particles smaller than 200 nm are considered to be small enough to be removed as foreign objects 
from the host into the lymphatic system whereas particles between 200 and 500 nm need to be transported 
within immune cells such as macrophages and consequently get phagocytosed (Danhier et al., 2012). 
DLS techniques report on the size of NPs within a suspension. However, it is possible to obtain the size 
of NPs in a dry state using SEM image analysis. Although we do not report here on NP size based on 
SEM we did observe that the NPs appear to be smaller on the SEM images compared to being in 
dispersion. This is expected since NPs within a suspension are hydrated and the hydrodynamic diameter 
obtained from DLS analysis includes measurement of a layer of solvent around the particles 
(Bhattacharjee, 2016). The main purpose of the SEM analysis was to gain insights into the morphology 
of our synthesized particles. SEM results demonstrated that all our NPs are spherical (Figure 3.4), this 
includes the 2% and 5% C-PLGA NPs (not shown). This is generally expected of polymer NPs that tend 
to naturally undertake a spherical geometry in an attempt to minimize the surface tension (Vauthier and 
Ponchel, no date) Spherical structures are inclined to be smaller with lower surface tension than their 







Figure 3.4. Representative SEM images of PLGA NPs and 8% C-PLGA NPs confirming a spherical 
conformation. Surface morphology was determines using a scanning electron microscope. The top 
panel was taken at a 200 nm and the bottom panel at a 1 µm range. All 4 of our different NP formulations 
proofed to have a spherical conformation and although not reported here, the 2% and 5% C-PLGA NP 
had a similar appearance.  
In addition to size, the zeta potential (surface charge) and PDI of the NPs all influence macrophage uptake 
and thus NP efficacy. The zeta potential refers to the net electrical charge on the particle surface and 
determines the stability of a NP suspension with zeta potential values close to ± 30 mV considered to 
reflect high stability of particle (Bhattacharjee, 2016; Zazo et al., 2016). Furthermore, the charge 
influences interactions with the environment within the host, including with proteins, tissue and cells 
(Zazo et al., 2016). Our NPs did not fall within the intended theoretical range, but for the purpose of this 
study they were stable; for the 1X wash NPs we observed a zeta potential range between -20.9 ± 2.3 mV 
and -23 ± 1.7 mV and for the 2X wash NPs a wider range of zeta potential values between -6.7 ± 6.0 mV 
to -22.4 ± 7.5 were reported with a statistically significant difference being detected between the 2% C-
PLGA and 8% C-PLGA NPs (P=0.049). In general, the closer the values are to 0 mV, the more unstable 
the suspension is. However, it is possible for very stable samples to show low zeta potential values due 
to factors beyond the scope of this study such as van der Waals forces that need to be accounted for 
(Bhattacharjee, 2016). Overall, the 1X wash NPs were expected to be more stable and the 2X wash 8% 
C-PLGA NP were expected to be the least stable of all the formulations with a zeta potential value of -
6.7 ± 6.0 mV. This low, unstable zeta potential highlights the relationship that exist between the surface 
charge and PDI. Surface charge can influence agglomeration that will consequently lead to higher PDI 
values. This is seen with the 8% C-PLGA NP that presented with the highest reported PDI value. A high 




surface charge indicates that there are strong repulsion forces between the NPs within a dispersion and 
this would be expected to minimize agglomeration, and consequently the size distribution of the NPs (Li 
et al., 2016).  
The PDI is a dimensionless parameter used to define the size distribution of NPs of colloids (Danaei et 
al., 2018). A colloid can either be monodispersed (PDI range 0.0 – 0.2) that indicates a uniform size 
distribution within a sample or be polydispersed (PDI range 0.4 – 1) that indicates a non-uniform size 
distribution due to factors such as agglomeration of particles or protein binding. The former is preferable. 
All our samples were monodispersed (PDI<0.4) with the 1X wash PDI values ranging between 0.16±0.01 
and 0.28±0.06, with a significant difference seen between the 2% C-PLGA and 8% C-PLGA NPs 
(P=0.049), and the 2X wash NPs having PDI values ranging between 0.25±0.01 and 0.34±0.07. The 
intricate relationship between NP size, PDI, zeta potential and shape is clearly highlighted by the 2X 
wash 8% C-PLGA NP. The weak surface charge (-6.7±6.0 mV) lead to more agglomeration as seen by 
the high PDI value (0.34±0.07) and SEM image which could contribute towards detection of larger NP 
sizes (380.1±26.6 nm).  
Taken together, the physicochemical characterization data indicated that we were able to synthesize 
stable NPs within the desired size range for further safety and efficacy analysis.  
3.3.2 Cytotoxicity assay 
According to the International Organization for Standardization (ISO), any compound resulting in a cell 
viability reduction below 80% is considered toxic towards the host (Basha et al., 2019). According to 
this standard we assessed the toxicity of 4 different NP formulations administered at 3 different 
concentrations (Figure 3.5) over a 72h period. We found all of them to be not cytotoxic towards 
RAW264.7 macrophages with the average values of three biological repeats remaining above 80% cell 
viability. This corresponds with previously published literature about the safety of polymeric NPs and in 
particular NPs synthesized from PLGA (Makadia et al., 2011; Dube et al., 2013; Tukulula et al., 2015; 






Figure 3.5. MTT cytotoxicity assessment of different C-PLGA NP formulations administered in 3 
different concentrations on murine RAW264.7 macrophages after 72h. A one-way ANOVA was 
conducted to compare the means of the administered NP concentrations at 72h for each of the 
respective 2X wash C-PLGA NP formulations (PLGA, 2%, 5%, and 8% C-PLGA). Each formulation was 
tested in quadruplicate and the results are representative of triplicate biological repeats and expressed 
as the mean ± SD. A Tukey's multiple comparisons post-hoc test was applied and a value of P<0.05 
was considered to be statistically significant.  Numbers on bars indicate the mean percentage cell 
viability corresponding with the Y-axis. *Indicate a statistically significant difference. Horizontal line 
through bars represent 80% toxicity cut-off as determined through ISO standards.  
No clear dose dependent trend was observed and variability in cell viability (as evidenced by the standard 
deviation values) was present. The variability was especially prevalent for the PLGA, 2% and 5% C-
PLGA NPs and not for the 8% C-PLGA NP. This can possibly be due to the instability observed for the 
8% C-PLGA NP (zeta potential=-6.7±6.0 mV; PDI=0.34±0.07) that contributed to a high degree of 
agglomeration of NPs suspended in D10. The presence of a lot of aggregates could suggest that fewer 
single particles could interact with the macrophages and be engulfed due to their large size thus remaining 
as clumps in the media.  
Interestingly, for the PLGA, 2% and 5% C-PLGA NPs it was observed that the addition of the particles 




is not uncommon and Li et al. (2016) found in a study utilizing gold nanoparticles that NP treatment 
caused proliferation of Human Periodontal Ligament Stem Cells (hPDLSCs), reaching cell viability 
values above 150% for the 60 nm NPs administered at a concentration of 28 μm. In this study, cell 
proliferation was observed where larger NP aggregates exceeded the receptor-mediated endocytosis 
threshold and nonspecifically adsorbed onto the surface of the cells (Hoshyar et al., 2016; Li et al., 2016). 
However, this explanation could be misinterpreted with regards to our particles as the NPs used in their 
study were approximately 60 nm in size and our NPs are almost 5X larger. In our case the increase in 
cell viability observed could be due to macrophage activation that leads to an increase in metabolic 
activity within the cells. When these results are translated to in vivo models, it can be speculated that 
heightened macrophage proliferation at the site of infection could enhance the recruitment of adaptive 
immune cells and consequently lead to a more powerful pathogen-specific inflammatory immune 
response. However, it is important to keep in mind that excessive inflammation can cause ‘cytokine 
storm’ at the site of the infection which can become clinically deleterious (Chiang et al., 2018). In line 
with stimulated macrophage proliferation, Tukulula et al. (2015) observed the same trend as reported 
here where THP-1 macrophages proliferated when treated with C-PLGA NPs likely due to cell 
stimulation. This could be explained by an in increase in the production of pro-inflammatory cytokines; 
therefore, to assess and confirm the theory of macrophage stimulation and subsequent proliferation we 
quantify and report on inflammatory cytokine production within Chapter 4. Notably, the NPs might not 
specifically induce cell proliferation but stimulate mitochondrial activity that increases the presence of 
important hydrogenase enzymes. As mentioned previously, the MTT assay depends on metabolically 
active cells to reduce the tetrazolium salt into formazan crystals. However, enhanced metabolic activity 
does not primarily indicate cell proliferation thus depicting false positive growth.  A major shortcoming 
of the MTT assay is that this assay does not accurately represent cell numbers and these findings might 
be misinterpreted and further investigation into the macrophage response is necessary.      
3.4 Conclusion 
We have successfully synthesized stable, spherical PLGA and 2%, 5% and 8% C-PLGA NPs within the 
desired size range as characterized by DLS techniques and SEM image analysis. The safety and 
biocompatibility of the particles were tested and confirmed on RAW264.7 macrophages. In the following 
chapter we assess the killing efficacy of these particles on M. tuberculosis-infected RAW264.7 






 Characterization of Intracellular nanoparticle activity 
In this chapter the ability of curdlan–functionalised poly(lactide-co-glycolide) nanoparticles (C-PLGA 
NPs) to inhibit the intracellular growth of Mycobacterium tuberculosis was assessed. RAW264.7 murine 
macrophages were infected with a luminescent strain of M. tuberculosis that enables us to track cell 
viability over time. An attenuated strain suitable for use within a BSL-2 setting was used. Alterations in 
luminescence provide a real time quantitative proxy of changes in bacterial cell numbers. A Luminex 
multiplex assay is conducted to detect the presence of 6 pro-inflammatory cytokines to determine if 
sufficient immune stimulation occurs through the C-PLGA NP-receptor interaction that will possibly 
contribute towards the eradication of bacilli.  
My contribution: Assessment of Intracellular NP efficacy  
  Supernatant collection and preparation for Luminex assay 
  Colony forming unit determination 




Liquid mycobacterial cultures were grown in 7H9-OGT – 7H9 (Becton Dickinson), supplemented with 
10% oleic acid–albumin–dextrose– catalase (OADC; Becton Dickinson, NJ, United States), 0.2% (v/v) 
glycerol (Sigma-Aldrich), 0.05% (v/v), Tween-80 (Sigma-Aldrich). Solid cultures were grown on 7H10 
agar (Becton Dickinson, NJ, United States). Additional supplements included pantohenate (24 μg/mL), 
leucine (50 μg/mL), kanamycin (25 μg/mL) (Sigma-Aldrich), hygromycin (50 μg/mL) (Invitrogen). 
RAW264.7 macrophages (ATCC TIB-71) were cultured and maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) (ThermoFisher) supplemented with 10% Fetal Bovine Serum (FBS) (ThermoFisher). 
Secreted cytokines were analysed using a customized mouse Multiplex R&D luminex kit (WhiteSci).  
4.1.2. Equipment 
Thermo Steri-Cycle CO2 incubator (Marshall Scientific), Labotec water bath (Labotec), Labotec Orbital 
shaking incubator (Labotec), Bath sonicator (SCIENTECH, Labotec), Probe sonicator (QSONICA), 
Labnet Prism microcentrifuge (Labnet), Spectrophotometer (Thomas Scientific), Labotec Orbital 
Shaking incubator (Labotec), FLUOstar Omega plate reader (BMG LABTECH), Bio Plex platform (Bio 





4.2.1. Bacterial strains and culture.  
Table 4.1 describes the M. tuberculosis strains utilized in this study. Mycobacterial cells were cultured 
in 7H9 supplemented with 10% OADC, 0.2% (v/v) glycerol, 0.05% (v/v) Tween-80 (7H9-OGT), and 
the necessary antibiotics for plasmid maintenance (kanamycin (25 µg/mL), hygromycin (50 µg/mL)). 
Additionally, M. tuberculosis ΔleuDΔpanD liquid cultures were supplemented with leucine (50 μg/mL) 
and pantothenate (24 μg/mL) and incubated at 37 °C with shaking at 180 rpm. Reporter strains expressing 
the bacterial luciferase operon of plasmid pMV306hsp + LuxCDABE (Andreu et al., 2010) were 
previously obtained through electroporation as describe by Snapper et al. (1990). Bioluminescence from 
LuxCDABE gene expression was used to measure the changes in bacterial numbers for both the M. 
tuberculosis ΔleuDΔpanD::pMV306hsp+lux strain and M. tuberculosis ΔleuDΔpanD wild-type (WT) 
reference strain. Solid cultures of M. tuberculosis ΔleuDΔpanD::pMV306hsp+lux were grown on 7H10 
agar containing leucine (50 μg/mL) and pantothenate (24 μg/mL) Plasmid pMV306hsp + LuxCDABE 
was obtained from Addgene; reference number 26155.  
Table 4.1. Strains and plasmids used in the study.  
Strain/plasmid Description Source 
M. tuberculosis ΔleuDΔpanD  Double leucine and 
pantothenate auxotroph  
HygR  




M. tuberculosis ΔleuDΔpanD 
transformed with plasmid 
pMV306hsp + LuxCDABE 
Episomal 
KanR 
pMV306hsp + LuxCDABE 
(Andreu et al., 2010) Addgene 
plasmid number 26155 
KanR, kanamycin resistant, HygR, hygromycin resistant 
4.2.2. Assessing the intracellular killing efficacy of C-PLGA NPs 
RAW264.7 cells were seeded at a concentration of 5×104 cells per well in a white solid bottom, 96-well 
tissue culture plate and incubated overnight at 37°C, 5% CO2 (Figure 4.1). Macrophage cells were 
infected with M. tuberculosis ΔleuDΔpanD::pMV306hsp+lux and M. tuberculosis ΔleuDΔpanD at an 
MOI of 10:1. Sampson et al. (2004) and Mouton et al. (2019) have thoroughly characterized and 
compared M. tuberculosis ΔleuDΔpanD with non-attenuated M. tuberculosis H37Rv and provided 
comprehensive evidence to support the use of this attenuated strain as a model organism in TB research. 
In preparation for the infection, the mycobacterial cells were sonicated at 37 kHz for 12 minutes to 
disperse clumps and filtered through a 40 μm cell strainer. Cells were washed in D10 and the absorbance 
(OD600) adjusted to 1. This was achieved by measuring the OD of the bacterial cultures prior to washing 
and then resuspending the cell pellet in a volume of D10 that would result in an adjusted OD600 = 1. The 
D10 media was continuously supplemented with leucine (50 μg/mL) and pantothenate (24 μg/mL) to 
support the growth of M. tuberculosis ΔleuDΔpanD cells. Once absorbance was adjusted, 100 μL of cell 




period, cells were washed once with PBS and 200 μL D10 containing (1:100) penicillin/streptomycin 
was added to the wells and incubated at 37°C, 5% CO2 for 1 h to kill any remaining extracellular, 
unphagocytosed bacteria. Cells were then washed three times with PBS. To the NP treated wells, 100 μL 
fresh D10 and 100 μL of the desired NP formulation suspended in D10 (supplemented with leucine (50 
μg/mL) and pantothenate (24 μg/mL)) was added. NPs were prepared as mentioned in Chapter 3 and 
UV-sterilized for 30 minutes before administration. Rifampicin treated wells (2 μg/mL) (positive 
control), M. tuberculosis ΔleuDΔpanD::pMV306hsp+lux untreated wells (negative control), and M. 
tuberculosis ΔleuDΔpanD untreated wells (background luminescence control) received 200 μL fresh 
D10 only (supplemented with leucine (50 μg/mL) and pantothenate (24 μg/mL)). In addition to untreated 
in vitro M. tuberculosis ΔleuDΔpanD::pMV306hsp+lux, in vitro M. tuberculosis 
ΔleuDΔpanD::pMV306hsp+lux were also treated with each of the NP formulations as a proof of concept 
highlighting the need for immune stimulation in the functioning of the particles. Based on the MTT 
cytotoxicity results it was decided to administer the 4 NP formulations at a concentration of 5 mg/mL 
since no toxicity was observed at this concentration after 72h. Each treatment was evaluated in 
quadruplicate (technical repeats) and the experiment itself done in triplicate (biological repeats) (Figure 
4.1).  
 
Figure 4.1. Typical plate layout used to assess the growth inhibitory potential of C-PLGA NPs. 
RAW264.7 macrophages were seeded at 5x104 cells/well and infected with M. tuberculosis 
ΔleuDΔpanD::pMV306hsp-lux and M. tuberculosis ΔleuDΔpanD wild-type at an effective MOI of 10:1. 
PLGA and 2%, 5%, and 8% C-PLGA NPs were administered at 5 mg/mL and luminescence readings 
were obtained at 24h, 48h and 72h. Intracellular controls included rifampicin (2 μg/mL) treated M. 
tuberculosis ΔleuDΔpanD::pMV306hsp+lux (positive control), untreated M. tuberculosis 
ΔleuDΔpanD::pMV306hsp+lux (negative control), and untreated M. tuberculosis ΔleuDΔpanD 
(background luminescence control). In addition to NP treated in vitro M. tuberculosis ΔleuDΔpanD, 
untreated M. tuberculosis ΔleuDΔpanD was added to indicate the unrestricted growth of the bacilli. Each 
treatment was tested in quadruplicate (technical repeats) and the experiment was repeated three times 
(biological repeats).  
In vitro Lux 
In vitro Lux + PLGA 
In vitro Lux + 2% C-PLGA 
In vitro Lux + 5% C-PLGA 
In vitro Lux + 8% C-PLGA 
Intracellular Lux 
Intracellular Lux + Rifampicin 
Intracellular Lux + PLGA 
Intracellular Lux + 2% C-PLGA 
Intracellular Lux + 5% C-PLGA 
Intracellular Lux + 8% C-PLGA 
Intracellular 
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Bioluminescence of the bacterial luciferase operon on the pMV306hsp+LuxCDABE provides a real time 
proxy of bacterial cell numbers and was used to measure the intracellular bacterial load at 24h, 48h and 
72h. A FLUOstar microplate reader was used and the luminescence gain setting automatically adjusted 
to 3600. The mean luminescence of the WT M. tuberculosis ΔleuDΔpanD cells was subtracted from each 
of the respective wells to obtain the plotted relative light units (RLU’S). Confirmatory colony forming 
unit (CFU) plating was done after 72h on 7H10 agar supplemented with 10% OADC, 0.2% (v/v) glycerol, 
1eucine (50 μg/mL) and pantothenate (24 μg/mL). Briefly, after removal of the supernatant, macrophages 
were lysed with dH2O and serial dilutions of the lysates plated and incubated at 37 ˚C for 21 days.  
4.2.3 Quantification of cytokines by multiplex luminex assay  
A customized mouse Multiplex Immunoassay (R&D Systems, WhiteSci) was used to simultaneously 
quantify the following analytes: Interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), 
interleukin (IL)-1β, IL-4, IL-10, and IL-12. The assay was performed according to the manufacturer’s 
instructions and the cytokine concentrations measured on a Bio-Plex platform (Bio Plex TM, Bio-Rad 
laboratories).  
Briefly, cell culture supernatants of the macrophage only controls, untreated macrophages containing M. 
tuberculosis ΔleuDΔpanD::pMV306hsp-lux, and M. tuberculosis ΔleuDΔpanD::pMV306hsp-lux 
treated with each of the 4 different NP formulations (PLGA, 2%, 5% and 8% C-PLGA) were collected. 
The cell supernatants were collected in Spin-X centrifuge tubes and possible extracellular bacilli were 
removed by centrifugation (1 minute, 10 000 rpm) and the flow-through was stored at -20 ˚C. 
4.2.4 Statistical analysis 
Luminescence data were analysed using GraphPad Prism v7.05 and expressed as the mean ± standard 
deviation (n=?). Differences between the bioluminescence means were analyzed with a two-way 
ANOVA and a one-way ANOVA was used for both CFU and cytokine excretion analysis. Observable 
differences were considered to be statistically significant if the calculated p-value was less than 0.05. If 
a statistically significant difference was identified, a Post hoc test would be performed to specify between 
which formulations the difference lie. 
For luminex analysis on the Bio-Plex platform, the transformed mean fluorescent intensity values of each 
cytokine was used to determine the correlation coefficient (r2>0) for the standard curves and the median 
fluorescent intensities was determined by the Bio-Plex manager software. A standard curve ranging from 
12 – 3060 pg/ml for IFN-γ, 3 – 788 pg/ml for TNF-α, 249 – 60453 pg/ml for IL-1β, 62 – 15110 pg/ml 
for IL-4, 12 – 3029 pg/ml for IL-10 and 43-10295 pg/ml for IL-12 was used in the assay. Analytes 
containing below Out Of Range (<OOR) values (concentrations too low to be detected) were omitted for 
further interpretation. 
4.3 Results and discussion 
4.3.1 Assessing the intracellular killing efficacy of C-PLGA NPs  
The MTT assay demonstrated no cytotoxicity for all four 2X wash NP formulations at a concentration 




suspension could increase the likelihood of cell stimulation leading to mycobacterial killing, and hence 
5 mg/mL was selected for the killing assays. Since no obvious difference was observed in the physico-
chemical properties of the 1X wash and 2X wash NPs, we decided to utilize 1X wash NPs to assess the 
effect of NPs on intracellular mycobacteria. In vitro cultured M. tuberculosis 
ΔleuDΔpanD::pMV306hsp-lux (Figure 4.2A, S4.1A) and intracellular M. tuberculosis 
ΔleuDΔpanD::pMV306hsp-lux (Figure 4.2B, S4.1B) were treated with 5 mg/mL of the PLGA, 2%, 5% 
and 8% w/w C-PLGA NPs and the expression of bioluminescence was tracked over a 3 day period using 
a microplate reader. A rifampicin (2 μg/mL) treated positive control was included to provide an indication 
of what is expected if bacterial cell death is occurring. Rifampicin was chosen due to its important role 
as one of the frontline anti-TB drugs. Additionally, untreated, negative controls were incorporated into 

























Figure 4.2. Effect of NPs on M. tuberculosis cell numbers over time. In vitro- cultured M. 
tuberculosis ΔleuDΔpanD::pMV306hsp-lux (A) cell numbers were compared with intracellular M. 
tuberculosis ΔleuDΔpanD::pMV306hsp-lux within RAW264.7 macrophages (B), by tracking 
luminescence over 72h. The intracellular and in vitro cultures were treated with 1X wash PLGA, 2%, 5% 
and 8% C-PLGA NPs at a concentration of 5 mg/mL. Untreated controls were incorporated as well as 
rifampicin (2 μg/mL) treated controls for the intracellular mycobacterial cells. Data is expressed as the 
mean of three biological repeats (quadruplicate technical repeats) with error bars indicating ±SD. A two-
way ANOVA was conducted between the different treatments followed by Tukey's multiple comparisons 
test and a P<0.05 value was considered to be statistically significant. For the in vitro cultures (A) the 
only statistically significant difference was between the untreated controls and the 2% C-PLGA NP 
(P=0.005) and 8% C-PLGA NP (P=0.019) treated cells, respectively. With regards to the intracellular 
bacilli a statistically significant difference was detected between the rifampicin treated controls and the 
untreated cells (P=0.0005), the PLGA NP (P<0.0001), 2% C-PLGA NP (P<0.0001), 5% C-PLGA NP 
(P<0.0001) and 8% C-PLGA NP (P=0.001) treated cells, respectively. MP - Macrophage; Lux - M. 






For both the in vitro and intracellular bacteria (Figure 4.2A & B, S4.1A & 4.1B), our results show the 
same growth trend between the NP treated cells and the untreated controls up to 48h but at the 72h time-
point the untreated controls plateau and the NP treated wells tended to increase in cell numbers. For the 
intracellular rifampicin treated control a reduction in RLU’s is observed immediately from the 24h time-
point as is expected from a bactericidal agent (Figure 4.2B).  
The main reason for assessing NP efficacy on in vitro cultures was to provide a proof of concept on the 
functioning of host-directed therapeutic NPs. Theoretically no growth inhibitory effect is expected on in 
vitro cultured M. tuberculosis ΔleuDΔpanD::pMV306hsp-lux compared to intracellular M. tuberculosis 
ΔleuDΔpanD::pMV306hsp-lux. The curdlan on the surface of the NPs is expected to interact with the 
Dectin-1 receptor on macrophages thus stimulating a macrophage-specific antibacterial effect (Tukulula 
et al., 2015, 2018). This is supported by our in vitro results where no reduction is seen in bacterial 
luminescence compared to that of the untreated control (Figure 4.2A, S4.1A). It appeared that the 
addition of NPs lead to heightened expression of bioluminescence for the in vitro cultures although the 
only statistically significant difference detected was between the untreated M. tuberculosis 
ΔleuDΔpanD::pMV306hsp-lux and bacilli treated with the 2% and 5% C-PLGA NPs, respectively 
(P<0.05).  
Contrary to what was expected we did not observe a reduction in bacterial luminescence for the NP 
treated intracellular cultures compared to the untreated controls and no specific particle was significantly 
superior to another (Figure 4.2B, S4.1B). A statistically significant difference was detected through a 
Tukey's multiple comparison post-hoc test was between each of the four NP formulations and the 
rifampicin treated control (P<0.05), respectively. It was confirmed that the NPs themselves do not 
contribute towards an increase in the detected bioluminescence (data not shown). This suggested that the 
relatively high RLU’s observed for the NP treated wells could be due to the enhanced growth of 
intracellular bacteria or the lysis of macrophages that release luminescent bacteria into the extracellular 
space. For the latter, the released intracellular bacteria could then grow unhindered in the media and thus 
contribute to misleading bioluminescence results.  
Prior to assessing the efficacy of the NPs the MTT cytotoxicity assay had been performed for the 2X 
wash NPs only (Figure 3.5). The assay was not initially carried out for the 1X wash NPs as no apparent 
physico-chemical difference was observed and the assumption was made that similar cytotoxicity as well 
as efficacy results would be obtained. However, after observing the unexpected efficacy results, a single 
biological repeat was completed with the 8% C-PLGA NPs (Figure 4.3).  Our results show a time- and 
dose-dependent toxic effect on the macrophages and a consequent drop in cell viability below 80% 
compared to the untreated controls. Due to time constraints toxicity testing of the 1X wash NPs was only 
















Figure 4.3. MTT cytotoxicity assay with the 1X wash 8% C-PLGA NPs: RAW264.7 macrophages 
were seeded at 2,5X104 cells/well after which 1X wash 8% C-PLGA NPs were administered at 1 mg/mL, 
2,5 mg/mL and 5 mg/mL and absorbance obtained over a 3 day period. A two-way ANOVA was 
conducted to compare the means of the administered NP concentrations at each time-point with the 
untreated control. Significance was tested with a Tukey's multiple comparisons test and a P<0.05 value 
was considered to be statistically significant. The results are representative of a single biological repeat 
expressed as the mean of quadruplicate technical repeats ± SD. The NPs show a dose- and time-
dependent toxic effect on the macrophages with only the 24h time point remaining above the 80% cell 
viability cut-off line. From 48h onwards all the treatments show a statistically significant drop in cell 
viability compared to the untreated controls (P<0.05). 
The apparent toxicity of the 1X wash NPs might contribute towards lysis of the macrophages thus 
releasing luminescent bacteria into the extracellular space that contribute towards inaccurately high 
luminescent readings indicated in figure 4.2B. We assessed this theory by replacing the media of a single 
infection (biological repeat 3; Figure S4.1) at the 72h time-point and repeating the measurement. We 
found that an obvious drop was observed in RLU’s when comparing the measurements at the single time-
point before and after media replacement for the NP treated cells (Figure 4.4).  A possible explanation 
for the observed toxicity and release of bacteria might be that 1X wash NPs dispersed with more ease in 
D10 compared to 2X wash NPs. This could indicate that aggregates might have been present in the 2X 
wash NP suspension used for initial MTT cytotoxicity assays; for the more evenly suspended 1X wash 
NPs more particles could be taken up by the macrophages thus stimulating macrophages more 





Figure 4.4. Assessing possible 1X wash NP toxicity-related cell lysis. RAW264.7 macrophages 
were infected with M. tuberculosis ΔleuDΔpanD::pMV306hsp-lux at an MOI 10:1. The intracellular 
cultures were treated with 1X wash PLGA, 2%, 5% and 8% C-PLGA NPs at a concentration of 5 mg/mL. 
Untreated controls were incorporated as well as rifampicin (2 μg/mL) treated controls. A two-way 
ANOVA was used to analyze the data and a Sidak’s multiple comparisons test identified significant 
differences (P<0.05). *Indicate statistically significant differences. Data expressed as the mean of 
quadruplicate technical repeats with error bars indicating ±SD. At the 72h time-point, exclusively, the 
media was replaced with fresh D10 and bioluminescence readings were repeated. An obvious reduction 
in bioluminescence is present for each of the NP treated wells between the before and after wash 
columns.  
4.3.1.2. Assessing mycobacterial killing using CFU plating 
Contradictory to detected bioluminescence, confirmatory CFU plating of the 2%, 5% and 8% w/w C-
PLGA NP treated intracellular mycobacteria showed a trend towards a reduction in viable cell numbers 
(Figure 4.5, S4.2). However, a Tukey’s multiple comparisons test indicated no clear statistically 
significant difference between the different NP formulations (P>0.05). These distinct results were 
unexpected since Andreu et al. (2013) extensively showed bioluminescence readings to correlate with 
CFU readouts under various intracellular and in vitro conditions including antibiotic treatment. A simple 
explanation for these distinct findings might be the aforementioned possible toxicity that leads to cell 
lysis and bacterial release into the extracellular space and hence confounds interpretation of the killing 
efficacy data. Further investigation is therefore required. However, should the observed difference in 
killing efficiency between curdlan loaded NPs and the PLGA only NPs prove to be true, it could indicate 
that possible growth inhibition could be due the speculated curdlan-receptor interaction that stimulates 




(Wagener et al., 2018). This pathway upregulates the production of oxidative species, Ca2+ levels, various 
important pro-inflammatory cytokines such as TNF-α and IL-12 as well as enhancing the phagocytic 
tendency of particles compared to unloaded NPs into macrophages (Dube et al., 2014; Tukulula et al., 


















Figure 4.5. Determination of intracellular M. tuberculosis ΔleuDΔpanD::pMV306hsp-lux burden 
by CFU plating. RAW264.7 macrophages were infected with M. tuberculosis 
ΔleuDΔpanD::pMV306hsp-lux and treated with PLGA, 2%, 5% and 8% C-PLGA NPs for 72h and 
compared to untreated controls. Macrophages were lysed after 72h and the cells plated on 7H10 agar 
supplemented with leucine and pantothenate. Agar plates were incubated at 37 ˚C for 21 days. Data 
represents three biological repeats (quadruplicate technical repeats) with error bars indicating ±SD. A 
one-way ANOVA was used to analyze the data and a Tukey's multiple comparisons test confirmed no 















4.3.2 Cytokine quantification 
Stimulation of the NF-κB pathway through curdlan-dectin-1 interactions has been implicated numerous 
times in the production of important pro-inflammatory cytokines that play a central role in an effective 
inhibitory immune response against M. tuberculosis (Hetland et al., 1998; Dube et al., 2013; Zhu et al., 
2015; Bouchemal et al., 2019). From our panel of six cytokines that included IFN-γ, TNF-α, IL-1β, IL-
4, IL-10, and -IL-12, we found that all the analytes were out of range (<OOR) except TNF-α. TNF-α 
secretion levels were significantly upregulated (P<0.0001) in the supernatant of the M. tuberculosis-
infected macrophages treated with 2%, 5% and 8% C-PLGA NPs compared to PLGA only NP treated 
cells, the untreated controls and unstimulated-uninfected macrophages (Figure 4.6).  
 
Figure 4.6. TNF-α cytokine secretion by RAW264.7 murine macrophages due to NP stimulation. 
RAW264.7 macrophages were infected with M. tuberculosis ΔleuDΔpanD::pMV306hsp-lux and treated 
with PLGA, 2%, 5% and 8% C-PLGA NPs at a concentration of 5 mg/mL. The supernatant of the 
macrophage-only control as well as untreated control was collected together with the NP treated wells 
after 72h and cytokine levels were quantified with a mouse Multiplex luminex kit. The total cytokine panel 
consisted out of 6 different cytokines; however, only TNF-α was within a detectable range. Data 
represents duplicate biological repeats (triplicate technical repeats) and the assay was performed in 
duplicate. A one-way ANOVA was conducted between the different treatments followed by a Tukey's 
multiple comparisons test and a P<0.05 value was considered to be statistically significant.  
However, no statistically significant difference was observed between the 2%, 5% and 8% w/w C-PLGA 
NP treated cells indicating that stimulation of cytokine secretion is not dependent on the amount of 




speculated that this could be due to receptor saturation and that the macrophage could not be further 
stimulated thus reaching a plateau. The cytokine stimulating effect of curdlan present on the NPs 
correlated with a reduction in CFU counts for the 2%, 5% and 8% w/w C-PLGA NPs (Figure 4.5). The 
importance of this pro-inflammatory cytokine in activating macrophages and reducing bacterial burdens 
is well documented and various studies have shown the aggravation of TB pathological outcomes with 
the addition of TNF-α neutralizing agents (Churchyard et al., 2009; Cavalcanti et al., 2012). In one of 
these studies, Lin et al. (2010) showed with cynomolgus macaques that treatment with TNF-α 
neutralizing agents lead to complete disease dissemination by 8 weeks post-infection and that anti-TNF-
α agents caused disease reactivation in latently infected subjects.  
Our current bacilli killing results based on luminescence and CFU readouts are inconclusive and further 
investigation is a necessity. However, the detection of TNF-α secretion in the cell supernatant suggest 
the potential immune modulatory effects of the curdlan which in turn could contribute towards bacterial 
killing. The direct growth inhibitory effect of curdlan on intracellular M. tuberculosis has recently been 
demonstrated by Negi et al. (2019); however, curdlan was exploited on its own without NPs acting as a 
form of carrier. In a mouse study the authors showed that the growth inhibitory effect observed on 
intracellular M. tuberculosis is due to activation of the STAT-1 and NF-κB pathways that leads to the 
production of nitric oxide (NO) and various important pro-inflammatory cytokines especially IL-1β, IL-
12, TNF-α, and IL-6. Furthermore these authors showed with in vivo assessments that treatment with 
curdlan increases the pool of Th1 and Th17 cells and leads to an increase in memory CD4 T cells (Negi 
et al., 2019). The killing effect of curdlan is not limited to M. tuberculosis alone and their findings are 
further supported by (Ghosh et al., 2013) who showed similar in vivo immunomodulatory effects of 
curdlan on eliminating Visceral Leishmaniasis. Similar to Negi et al., these authors reported significant 
upregulation of NO as well as Th1 and Th17 associated cytokines such as IL-1β and IL-22 (Ghosh et al., 
2013). Stimulation of both a Th1 and Th17 immune response is promising since both these immune 
reaction are stimulated by M. tuberculosis infections (Torrado et al., 2011; Lemmer et al., 2015; Lyadova 
et al., 2015). A Th1 immune response is associated with protection against TB and Th17 with TB 
pathology, respectively, thus a fine balance between the two responses is considered important to control 
the outcome of TB and the consequent overproduction of Th17 related cytokines is linked with severe 
tissue damage (Torrado et al., 2011; Lyadova et al., 2015). These statements are further supported by the 
observed elevated TNF-α levels; TNF-α is considered an important co-factor together with IL-1β 
involved in TH17 immune cell differentiation and elevated expression of TNF-α is associated with an in 
increase in IL-17 immune cell production (Torrado et al., 2011). Hence, overproduction of TNF-α could 
indicate TB pathology and tissue damage but more cytokines should be analysed to further assess the 
exact immune milieu, and determine whether this is likely to deliver a favourable outcome or not. This 
would help to establish the potential of curdlan as a host directed therapeutic compound to successfully 
maintain an effective and safe immune response especially since excessive inflammation is one the most 
unknown and feared outcomes of HDT.  
M. tuberculosis-specific killing remains to be thoroughly investigated with regards to NPs functionalised 
with curdlan. A proof of concept study conducted previously by our group highlighted the potential of 
curdlan-functionalised polycaprolactone (C-PCL) NPs to stimulate a macrophage-specific immune 
response that lead to the reduction in M. tuberculosis cell numbers (Figure 4.7). This effect was only 
observed for intracellular bacilli and not for in vitro cultures thus highlighting the need for host cell 
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Figure 4.7. Luminescence expression of C-PCL NP treated intracellular M. tuberculosis. 
RAW264.7 macrophages were infected with M. tuberculosis H37Rv::pMV306hsp-lux and the NPs were 
administered to intracellular and in vitro cultures at 0,1 mg/mL. Rifampicin (2 μg/mL) treated and 
untreated controls were added as positive and negative controls, respectively. Cell viability was tracked 
over a 3 day period using luminescence as a proxy for cell numbers. Three different NPs were assessed 
containing different curdlan loads; C1 – 0,1% w/w C-PCL, C2- 1% w/w C-PCL, 2% w/w C-PCL. (Dr. 
Jomien Mouton, unpublished). 
In literature thus far the majority of studies of functionalised NPs aim to provide insights into the 
macrophage-specific immune response stimulated through the ligand-receptor interactions. Thus, these 
studies merely provide insights about the potential of curdlan-functionalised NPs to contribute towards 
killing intracellular bacilli by illuminating the stimulated antibacterial immune responses. In a study done 
by (Tukulula et al., 2015) the authors designed C-PLGA NPs and demonstrated the capability of the NPs 
to stimulate the production of phosphorylated ERK, an upstream mediator of oxidative species such as 
NO known to be toxic to intracellular bacteria. The macrophage-specific targeting of curdlan NPs are 
furthermore established in 2018 by Tukulula et al. and supported by Basha et al. (2019) that exploited 
curdlan NPs to specifically target anti-TB drugs to macrophages. Hence, in addition to illuminating the 
target specificity of curdlan they also indicate the potential of these NPs to effectively release drugs at 
the site of infection.  
4.4 Conclusion 
We have assessed the killing potential of C-PLGA NPs using intracellular M. tuberculosis 
ΔleuDΔpanD::pMV306hsp-lux. Notably, the cytotoxicity assays (Chapter 3) and the killing efficacy 
assessments (Chapter 4) were performed in parallel, thus the complete data for cytotoxicity was not 
available at the time of initiating the killing efficacy assessments. The subsequently obtained data could 




cytotoxicity under the conditions used confounded interpretation of the killing assays, and this would 
require further investigation. However, the potential of curdlan-specific immune stimulation is supported 
by the upregulation of TNF-α in the supernatant of the 2%, 5% and 8% w/w C-PLGA NP treated cells. 
This confirms the immune stimulating capabilities of curdlan as highlighted in previously published 







Conclusion, limitations and future recommendations 
PLGA, 2%, 5% and 8% w/w C-PLGA NPs were successfully synthesized using the single emulsion 
solvent evaporation method. DLS analysis confirmed that the particles were in the desired size range and 
stable and uniform in aqueous suspension No statistically significant differences were observed when 
comparing the C-PLGA NPs and the PLGA NPs indicating the addition of curdlan up to 8% w/w does 
not alter these physico-chemical properties of the PLGA NPs and by our measures relative consistency 
was present throughout. We note though that previous studies have reported on possible batch-to-batch 
variability. This emphasizes the need to remain consistent throughout the synthesis process, and to take 
extreme care during the handling and production of NPs. Good record keeping on the quality and state 
of consumables and reagents, and consistency in the timing and circumstances during NP 
characterization is essential (Baer, 2018). For future studies, an additional control step to detect possible 
variability that might arise is the use of X-ray photoelectro spectroscopy (XPS), a sensitive surface 
analysis method able to identify the slightest alteration between surface properties of different NP batches 
(Baer, 2018). This might be an important step to incorporate when the yield of NPs needs to be up-scaled 
from laboratory use to commercial applications. Additionally, the incorporation of XPS could allow for 
more comprehensive characterization of the surface chemistry of the NPs and investigation of the 
biological behavior of these particles within the desired environment (Spampinato et al., 2016).  
An MTT assay was performed to assess the cytotoxicity of the NPs on RAW264.7 macrophages at NP 
concentrations of 1, 2.5 and 5 mg/mL. When performed for the 2X wash NPs, all 4 NP formulations 
stayed within the ISO guidelines and did not lead to a reduction below 80% in cell viability after 72h of 
treatment at each of the administered concentrations. We observed that the PLGA, 2% and 5% w/w C-
PLGA NPs stimulated macrophage proliferation that lead to viability values above 100%; however, high 
variability was observed (as indicated by the standard deviation). The same proliferation was not 
observed for the 8% w/w C-PLGA NPs. It is speculated that this could have been due to possible 
agglomeration in D10 since the 8% w/w C-PLGA NPs appeared to be the least stable of all the 
formulations with a low average zeta potential value of -6.7 ± 6.0 mV and relatively high PDI value of 
0.34 ± 0.07, and therefore a lower particle surface area (in comparison to less aggregated particles) would 
be present for interaction with the macrophages. Future studies are recommended to determine the 
particle properties in D10.  
Notably, the MTT assay has some limitations, and future studies could benefit from the incorporation of 
assays that provide more insight into cell numbers, metabolic state and cell death pathways. When using 
the MTT assay, a change in viability between treated and untreated controls can be over-or 
underestimated due to experimental manipulations such as pipetting errors leading to inconsistent cell 
numbers between the wells or unknown parameters including enzymatic reactions that interfere with the 
assay; these factors should be considered when results are interpreted. An important limitation of the 
MTT assay is that the reduction of tetrazolium does not accurately reflect cell numbers but is rather an 
indication of cell metabolism or the rate by which glycolytic NADH is produced (Riss et al., 2017). Cells 
that are actively growing will have a different metabolic rate than those that are deteriorating, those that 
have undergone differentiation and those that have grown into a confluent monolayer with not much 




activity it is possible that the polymer NPs has the potential to stimulate mitochondrial activity that 
contributes towards an increase in apparent cell viability readings and the consequent variability 
observed. An interesting possibility is that there might be heterogeneous macrophage responses, i.e. that 
NPs are stimulating mitochondrial activity in one cell while other cells are being killed due to toxicity. 
However, enhanced metabolic activity could overshadow possible toxicity contributing to false positive 
outcomes. Nevertheless, this will need to be further investigated through the use of available 
mitochondrial inhibitors that will give a clear indication if the polymer particles are affecting 
mitochondrial activity or stimulating macrophage proliferation. 
Alternatives to be considered for future assessments include ATP assays. These measure the production 
of ATP as an indicator of viable cells and are considered to be the most sensitive method to detect cell 
viability (Riss et al., 2017). The CellTiter-GLO® Luminescent Cell Viability Assay has the benefit of 
generating a stable luminescent reading as a result of immediate cell lysis after the addition of the ATP 
assay reagent. Another alternative is the RealTime-Glo® MT Cell Viability Assay that depends on the 
ability of live cells to convert a pro-substrate into a substrate that can be reduced by NanoLuc® Luciferase 
to produce a luminescent signal. Another option would be the use of live/dead assays with florescent 
readouts; these lend themselves to flow cytometric measurement, and would therefore provide 
population-wide readouts on a single cell level. This could provide insight into heterogeneous responses 
within the macrophage population. Finally, as a more cost-effective option, one could use the Trypan-
Blue exclusion assay that exploits the ability of the Trypan blue dye to only enter dead cells. Dead cells 
will be stained blue and can easily be differentiated from live cells and counted using a light microscope.  
Based on the positive MTT assay results, it was decided to administer 1X wash NPs at 5 mg/mL to 
optimize the prospect of curdlan-macrophage interactions for further experimentation. We infected 
macrophages with a double auxotrophic strain expressing the bacterial luciferase gene which enabled us 
to track luminescence over 72h after NP administration (Sampson et al., 2004; Andreu et al., 2010, 2013). 
After 72h it appeared that the PLGA, 2%, 5% and 8% C-PLGA NPs did not have a growth inhibitory 
infect on the intracellular bacilli and bacterial luminescence was observed to increase; however, we 
showed that this might be due to luminescent bacteria released into the extracellular space due to possible 
macrophage lysis. Unexpected toxicity of the NPs or possible over-stimulation might cause the 
macrophages to lift off from the microplate surface or induce cell lysis that release viable bacilli. Curdlan-
specific stimulation of the macrophages could induce excessive inflammation and the consequent 
upregulation of TNF-α. Although considered an important inflammatory mediator, in excessive amounts 
this cytokine can be associated with necrosis, a form of cell death that cause lysis of the macrophage and 
the release of viable M. tuberculosis bacilli in to immediate environment (Cavalcanti et al., 2012). It is 
important to find an inflammatory balance and an issue frequently arising with HDT is the possible 
induction of a cytokine storm; an excessive inflammatory response frequently associated with increased 
levels of TNF-α (Gustafson et al., 2016).  
Contrary to bioluminescence readings, confirmatory CFU plating showed that the 2%, 5% and 8% w/w 
C-PLGA NPs could have an inhibitory effect that corresponds with upregulated TNF-α secretion of these 
specific NPs compared to untreated and PLGA NP treated cells. Keeping the possibility of cell lysis in 
mind which would automatically reduce the amount of available cells to plate (since only adherent 
macrophages are lysed for release of bacteria), this could indicate that the presence of curdlan on the 
NPs, independent of the percentage (w/w), stimulate a macrophage-specific immune response. Based on 




Upregulation of TNF-α indicates successful immune stimulation through curdlan-macrophage 
interactions. However, the latter requires further testing to determine whether there is a true reduction in 
intracellular bacterial numbers, as well as to more thoroughly assess the phenotype of the macrophage 
following NP treatment. In addition to being a potent pro-inflammatory cytokine, TNF-α is a biomarker 
frequently associated with containment of TB in latently infected patients (Cavalcanti et al., 2012) and 
various studies have shown that the treatment with anti-TNF-α agents frequently lead to the reactivation 
of active TB disease (Jauregui-amezaga et al., 2013; Long et al., 2019). This could contribute towards 
discrepancies observed between the two cell viability measurements that identify different populations. 
Bioluminescence uses ATP as a biomarker (Andreu et al., 2012) for cell viability and thus has the 
capacity to detect viable and uncultivable cells (Venkateswaran et al., 2003). Whether this is the case 
here will require further investigation. 
Building on these results, further optimization and intracellular and in vivo characterization is essential. 
First, translating the results from murine macrophages into mouse studies will give a more clear 
indication of the impact of NPs within a fully functional in vivo immune system. While in vivo mouse 
studies can give a clear indication on what would happen within a complete immune response, this may 
not reflect certain aspects of human host responses. To gain some insight into the effect of NPs on human 
macrophages, studies could be performed in the THP-1 cell line, a human macrophage-like system. The 
addition of proteins and agitation into the system used for THP-1 studies will more closely simulate 
physiological conditions where factors such pH and enzymatic reactions could influence NP action. This 
will highlight potential protein binding and immune opsonization that might influence NP functioning 
and localization. To enhance NP efficacy, it is possible to incorporate conventional antibiotics through 
surface attachments or encapsulation thus simultaneously maximizing pathogen killing and controlling 
inflammation. Through this multimodal approach we can deliver drugs to the specific site of infection 
with enhanced intracellular uptake and the sustained release of anti-TB drugs within the cell that will 
contribute to a reduction in daily administered dosages (Ungaro et al., 2012).  
We hypothesized that C-PLGA NPs have the potential to elicit an antibacterial immune response. In this 
study, we showed that curdlan-containing PLGA NPs stimulated TNF- α production by macrophages. 
Further investigation is required to determine the impact of this on intracellular bacteria, and whether 
this will translate to bacterial killing. This study highlights the immune stimulating potential of C-PLGA 
NPs and that there is potential for these NPs to be further developed into a host directed therapy for the 






Figure S3.1. The physiochemical parameters of the 4 different NP formulations. The A) average 
size (nm), B) average PDI, C) and average zeta potential (mV) of the 1X wash PLGA, 2%, 5% and 8% 
C-PLGA NPs. Data represents triplicate repeats and error bars indicate ±SD. Samples were analyzed 
using a Malvern Zetasizer NanoZS90 at 25 ˚C. The data was analyzed using a one-way ANOVA 
followed by a Tukey's multiple comparisons test. A P<0.05 value was considered to be statistically 







Figure S3.2.The physiochemical parameters of the 4 different NP formulations. The A) average 
size (nm), B) average PDI, C) and average zeta potential (mV) of the 2X wash PLGA, 2%, 5% and 8% 
C-PLGA NPs. Data represents triplicate repeats and error bars indicate ±SD. Samples were analyzed 
using a Malvern Zetasizer NanoZS90 at 25 ˚C. The data was analyzed using a one-way ANOVA 
followed by a Tukey's multiple comparisons test. A P<0.05 value was considered to be statistically 































Infection 3 (Biological repeat 3) 
 
Figure S4.1. Expression of the bacterial luciferase operon on the pMV306hsp + LuxCDABE 
plasmid enables us to track intracellular M. tuberculosis cell numbers over time. In vitro- cultured 
M. tuberculosis ΔleuDΔpanD::pMV306hsp-lux (A) cell numbers were compared with intracellular M. 
tuberculosis ΔleuDΔpanD::pMV306hsp-lux within RAW264.7 macrophages (B), by tracking 
luminescence over 72h. The intracellular and in vitro cultures were treated with 1X wash PLGA, 2%, 5% 
and 8% C-PLGA NPs at a concentration of 5 mg/mL. Untreated controls were incorporated as well as 
rifampicin (2 μg/mL) treated controls for the intracellular mycobacterial cells. Data expressed as the 
mean of quadruplicate technical repeats with error bars indicating ±SD. A one-way ANOVA was 






significant determined through a Tukey’s multiple comparisons test. Each biological repeat is clustered 























Figure S1.2. CFU plating of M. tuberculosis ΔleuDΔpanD::pMV306hsp-lux. RAW264.7 
macrophages were infected with M. tuberculosis ΔleuDΔpanD::pMV306hsp-lux and treated with PLGA, 
2%, 5% and 8% C-PLGA NPs for 72h and compared to untreated controls. Macrophages were lysed 
after 72h and the cells plated on 7H10 agar supplemented with leucine and pantothenate. Agar plates 
were incubated at 37 ˚C for 21 days. Data represents quadruplicate technical repeats with error bars 
indicating ±SD. A one-way ANOVA was used to analyze the data and a Tukey's multiple comparisons 







Figure S2. TNF-α cytokine secretion by RAW264.7 murine macrophages due to NP stimulation. 
RAW264.7 macrophages were infected with M. tuberculosis ΔleuDΔpanD::pMV306hsp-lux and treated 
with PLGA, 2%, 5% and 8% C-PLGA NPs at a concentration of 5 mg/mL. The supernatant of the 
macrophage-only controls as well as untreated controls was collected together with the NP treated wells 
after 72h and cytokine levels were quantified with a mouse Multiplex luminex kit. The total cytokine panel 
consisted out of 6 different cytokines; however, only TNF-α was within a detectable range. Data 
represents triplicate technical repeats and the assay was performed in duplicate. A one-way ANOVA 
were conducted between the different treatments followed by a Tukey's multiple comparisons test and 
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